insulin detemir profile

Insulin Detemir: A recombinant long-acting insulin and hypoglycemic agent in which a MYRISTIC ACID is conjugated to a LYSINE at position B29. It is used to manage BLOOD GLUCOSE levels in patients with DIABETES MELLITUS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	16137271
CHEMBL ID	2104391
MeSH ID	M0274330

Synonym
169148-63-4
insulin,detemir,human
insulin detemir recombinant
detemir
insulin detemir
29(sup b)-(n(sup 6)-(1-oxotetradecyl)-l-lysine)-(1(sup a)-21(sup a)),(1(sup b)-29(sup b))-insulin (human)
nn304
nn 304
levemir
29(sup b)-(n(sup 6)-myristoyl-l-lysine)-30(sup b)-de-l-threonineinsulin (human)
29b-(n6-myristoyl-l-lysine)-30b-de-l-threonineinsulin (human)
CHEMBL2104391
unii-4ft78t86xv
nn-304
levemir innolet
levemir penfill
levemir flexpen
4ft78t86xv ,
insulin detemir [usan:inn:ban]
levemir insulin

Excerpt	Reference	Relevance
"Insulin detemir (IDet) is an insulin analog used to treat diabetes. "	( Probing the mechanism of reduced Brand, CL; Sturis, J, 2023)	2.35
"Insulin detemir is a lipidated insulin analogue that obtains a half-life extension by oligomerization and reversible binding to human serum albumin. "	( Investigations of Albumin-Insulin Detemir Complexes Using Molecular Dynamics Simulations and Free Energy Calculations. Bukrinski, JT; Harris, P; Peters, GHJ; Ryberg, LA; Sønderby, P, 2020)	2.3
"Insulin detemir (IDet) is a clinically available, slow-acting, synthetic analogue characterised by the conjugation of a C14 fatty acid."	( Exploration of temperature and shelf-life dependency of the therapeutically available Insulin Detemir. Adams, GG; Agugini, G; Beji, O; Dinu, V; Fedele, F; Fisk, ID; Gillis, RB; Gyasi-Antwi, P; Harding, SE; Huang, S; Jiwani, SI; Meal, A; Morgan, PS, 2020)	1.5
"Insulin detemir (DET) is a basal insulin analog that, in contrast to other long-acting forms of insulin, has significant weight-gain-sparing effects in diabetic patients. "	( Central effects of insulin detemir on feeding, body weight, and metabolism in rats. Chapman, CD; Currie, PJ; John, CS; Pi-Sunyer, FX; Vasselli, JR; Wall, DG, 2017)	2.23
"Insulin detemir is a basal insulin analog that causes less weight gain than other basal insulin formulations, including the current standard intermediate-long acting Neutral Protamine Hagedorn (NPH) insulin."	( Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial. Barkhof, F; Deijen, JB; Diamant, M; Drent, ML; Heijboer, AC; van Golen, LW; Veltman, DJ; Ĳzerman, RG, 2014)	1.51
"Insulin detemir is a long-acting insulin analogue and may represent a valuable treatment option for diabetic cats. "	( Insulin detemir treatment in diabetic cats in a practice setting. Bjornvad, CR; Hoelmkjaer, KM; Spodsberg, EM, 2015)	3.3
"Insulin detemir is a new basal insulin analogue with superiority to NPH insulin similar to that demonstrated by insulin glargine, though its duration of action appears to be shorter."	( New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. Roach, P, 2008)	1.07
"Insulin detemir is a basal insulin analog designed to produce a superior pharmacokinetic profile to basal formulations of human insulin. "	( Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study. Atabek, ME; Dizdarer, C; Emek, S; Isguven, P; Kurtoglu, S; Pirgon, O, 2009)	3.24
"Insulin detemir (Levemir) is a soluble human insulin analogue acylated with a 14-carbon fatty acid, which reversibly binds to albumin, thereby providing a more prolonged metabolic effect with lower variability as compared to NPH insulin taken as reference. "	( [Insulin detemir in the predictive study: results in patients with type 1 diabetes in the Belgian cohort]. Philips, JC; Scheen, AJ, 2009)	2.71
"Insulin detemir is a novel human insulin analog that does not show the usual propensity for weight gain in diabetic patients. "	( Evaluation of the lack of anorectic effect of intracerebroventricular insulin in rats. Bouman, SD; Clegg, DJ; Jessen, L, 2010)	1.8
"Insulin detemir is a basal insulin analog that provides effective therapeutic options for patients with type 1 and type 2 diabetes."	( An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. Raslova, K, 2010)	1.31
"Insulin detemir (Levemir®) is a long-acting insulin analogue indicated for use as basal insulin therapy in patients with type 1 or 2 diabetes mellitus. "	( Insulin detemir: a review of its use in the management of diabetes mellitus. Keating, GM, 2012)	3.26
"Insulin detemir is a soluble basal insulin analog with a unique mechanism of protracted action designed to reduce the variability associated with conventional basal insulins. "	( Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. De Leeuw, I; Draeger, E; Elte, JW; Haahr, H; Kristensen, A; Selam, JL; Skeie, S; Vague, P, 2003)	3.2
"Insulin detemir (NN-304) is a soluble, long-acting insulin analog being developed by Novo Nordisk for the potential treatment of type 1 and 2 diabetes. "	( Insulin detemir. Novo Nordisk. Barlocco, D, 2003)	3.2
"Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the limitations of conventional basal insulin formulations. "	( Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Abrams, P; Bartley, P; Draeger, E; Hanaire-Broutin, H; Heeg, JE; Home, P; Hylleberg, B; Landin-Olsson, M; Lang, H; Russell-Jones, D, 2004)	3.21
"Insulin detemir is a novel long-acting analogue of human insulin designed to overcome these practical limitations."	( Can we reduce hypoglycaemia with insulin detemir? Mathieu, C, 2004)	1.33
"Insulin detemir is a new long-acting soluble insulin analogue where protraction is achieved by reversible binding to albumin."	( At last, a weight neutral insulin? Fritsche, A; Häring, H, 2004)	1.04
"Insulin detemir (Levemir) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. "	( Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Chapman, TM; Perry, CM, 2004)	3.21
"Insulin detemir is a basal insulin analog that has been shown to improve glycemic control in patients with type 1 and type 2 diabetes."	( Insulin detemir--a new basal insulin analog. Goldman-Levine, JD; Lee, KW, 2005)	3.21
"Insulin detemir (Levemir) is a soluble long-acting human insulin analog acylated with a 14-carbon fatty acid. "	( Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. Chapman, TM; Perry, CM, 2005)	2.14
"Insulin detemir (Levemir) is a soluble long acting human insulin analogue acylated with a 14-carbon fatty acid. "	( [Insulin detemir (Levemir)]. Paquot, N; Philips, JC; Radermecker, RP; Scheen, AJ, 2005)	2.68
"Insulin detemir is a new basal insulin analogue recently available for commercial use in the UK."	( Insulin detemir: a new basal insulin analogue. Soran, H; Younis, N, 2006)	2.5
"Insulin detemir (Levemir) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. "	( [Insulin analogues: place of detemir (levemir)]. Dorchy, H; Sternon, J, )	1.57
"Insulin detemir (Levemir) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. "	( [Insulin analogues: place of detemir (Levemir)]. Dorchy, H; Sternon, J, 2006)	1.78
"Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin) and insulin glargine. "	( Insulin detemir: a long-acting insulin product. Jones, MC; Patel, M, 2006)	3.22
"Insulin detemir is a soluble long-acting human insulin analogue at neutral pH with a unique mechanism of action. "	( Insulin detemir in the treatment of type 1 and type 2 diabetes. Philips, JC; Scheen, A, 2006)	3.22
"Insulin detemir is a novel basal insulin analogue that has consistently been shown in randomized, controlled trials to have a weight-sparing effect (i.e."	( Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Davies, M; Hermansen, K, 2007)	1.57
"Insulin detemir is a basal insulin analog that can help patients move safely toward glycemic targets with less weight gain."	( Intensive diabetes therapy and body weight: focus on insulin detemir. Bush, MA, 2007)	1.31
"Insulin detemir is a novel long-acting insulin analogue with a unique mechanism underlying its prolonged duration of action. "	( Defining the role of insulin detemir in Basal insulin therapy. Morales, J, 2007)	2.1
"Insulin detemir (NN304) is a soluble basal insulin analog developed to cover basal insulin requirements. "	( Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Axelsen, M; Hermansen, K; Kristensen, A; Madsbad, S; Perrild, H, 2001)	2.01

Excerpt	Reference	Relevance
"Insulin detemir has a different profile of action on the central nervous system (CNS) than human insulin. "	( Insulin detemir is not transported across the blood-brain barrier. Banks, WA; Lynch, JL; Lynch, KM; Mooradian, AD; Morley, JE, 2010)	3.25
"Insulin detemir has a more predictable, protracted and consistent effect on blood glucose than neutral protamine Hagedorn (NPH) insulin, with less intrapatient variability in glycaemic control, compared with NPH insulin or insulin glargine."	( Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Chapman, TM; Perry, CM, 2004)	2.49
"Insulin detemir has a more predictable, protracted, and consistent effect on blood glucose than neutral protamine Hagedorn (NPH) insulin, with less intrapatient variability in glycemic control than NPH insulin or insulin glargine."	( Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. Chapman, TM; Perry, CM, 2005)	1.42
"Insulin detemir has a less variable pharmacokinetic profile than insulin suspension isophane or insulin ultralente."	( Insulin detemir in the treatment of type 1 and type 2 diabetes. Philips, JC; Scheen, A, 2006)	2.5
"Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally."	( Insulin detemir: A historical perspective on a modern basal insulin analogue. Abrahamson, MJ; Liebl, A; Meneghini, L, 2010)	2.52
"Insulin detemir has been found in clinical trials to be absorbed with very low variability. "	( The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Havelund, S; Jonassen, I; Kurtzhals, P; Markussen, J; Plum, A; Ribel, U; Vølund, A, 2004)	2.05
"Insulin detemir has shown weight neutrality in patients with type 1 diabetes and is associated with less weight gain than NPH insulin in clinical studies."	( Defining the role of insulin detemir in Basal insulin therapy. Morales, J, 2007)	1.38

Excerpt	Reference	Relevance
"Insulin detemir dosages were lower than reported dosages of other insulin types needed to maintain glycemic control, suggesting that insulin detemir should be used with caution, especially in small dogs."	( Detemir insulin for the treatment of diabetes mellitus in dogs. Boretti, FS; Corradini, S; Fracassi, F; Hafner, M; Reusch, CE; Sieber-Ruckstuhl, NS, 2015)	1.14
"Insulin detemir displays reduced induction of the Pparg2 adipocyte master gene and diminished effects on adipocyte differentiation and lipogenesis in human subcutaneous and visceral ASC, in spite of normal activation of proximal insulin signaling reactions. "	( Long-acting insulin analog detemir displays reduced effects on adipocyte differentiation of human subcutaneous and visceral adipose stem cells. Barbaro, M; Cignarelli, A; Ficarella, R; Giorgino, F; Laviola, L; Natalicchio, A; Nigro, P; Perrini, S; Peschechera, A; Porro, S; Puglisi, F, 2016)	1.88

Excerpt	Reference	Relevance
"Treatment with insulin detemir compared to NPH insulin found an RR for severe hypoglycaemia of 0.45 (95% CI 0.17 to 1.20; P = 0.11; ARR -0.9%, 95% CI -1.4 to 0.4; 5 trials, 1804 participants; very low-certainty evidence)."	( (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Berghold, A; Engler, J; Horvath, K; Jeitler, K; Semlitsch, T; Siebenhofer, A, 2020)	0.9
"Treatment with insulin detemir also reduced the incidence of serious hypoglycaemia."	( (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Berghold, A; Engler, J; Horvath, K; Jeitler, K; Semlitsch, T; Siebenhofer, A, 2020)	0.9
"Treatment with insulin detemir versus NPH insulin resulted in weight loss, paralleled by increased CBF in appetite-related brain regions in the resting state, in men with well-controlled type 1 diabetes. "	( Cerebral blood flow and glucose metabolism in appetite-related brain regions in type 1 diabetic patients after treatment with insulin detemir and NPH insulin: a randomized controlled crossover trial. Diamant, M; Drent, ML; Hensbergen, JF; Hoogma, RP; Huisman, MC; Lammertsma, AA; van Golen, LW; Ĳzerman, RG, 2013)	0.95
"Treatment with insulin detemir and aspart in patients with type 1 diabetes and recurrent severe hypoglycaemia resulted in a clinically significant reduced rate of severe hypoglycaemia compared with human insulin. "	( Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Beck-Nielsen, H; Christiansen, JS; Hougaard, P; Jensen, T; Kristensen, PL; Nørgaard, K; Parving, HH; Pedersen-Bjergaard, U; Perrild, H; Tarnow, L; Thorsteinsson, B, 2014)	0.76
"Treatment with insulin detemir was associated with fewer mild hypoglycaemic events than NPH insulin (mean rates of 26.3 vs. "	( Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Jendle, J; Lammert, M; Pollock, RF; Saraheimo, M; Thorsteinsson, B; Valentine, WJ, 2012)	0.94
"Treatment with insulin detemir for 6 months resulted in substantial benefits, including reduced HbA(1c), FPG and body weight, and improvements in nocturnal quality of life, without increasing hypoglycaemia."	( Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23). Abe, N; Kobayashi, M; Kuribayashi, N; Matoba, K; Oishi, M; Tomonaga, O; Yokoyama, H, 2012)	0.95
"Treatment with insulin detemir appears to require more frequent administration and higher insulin doses compared with insulin glargine in patients with type 2 diabetes, with 33% higher doses, on average, observed in this study. "	( Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir. Bryant, GA; Farris, KB; Horner, KE; McDanel, DL; Newkirk, EN, 2013)	0.96
"Treatment with insulin detemir resulted in more predictable glycemic control, with smoother plasma glucose profiles than NPH insulin and a significant reduction in the risk of hypoglycemia. "	( Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. De Leeuw, I; Draeger, E; Elte, JW; Haahr, H; Kristensen, A; Selam, JL; Skeie, S; Vague, P, 2003)	2.11
"Treatment with insulin detemir+/-OHA was associated with increases in quality-adjusted life expectancy of 0.309, 0.350, and 0.333 quality-adjusted life-years (QALYs) versus treatment with OHA alone, NPH+/-OHA, and insulin glargine+/-OHA, respectively."	( Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Cobden, D; Erny-Albrecht, KM; Palmer, AJ; Ray, JA; Roze, S; Valentine, WJ, )	0.79
"Treatment with insulin detemir (+/- OADs) significantly reduced mean haemoglobin A(1c) (HbA(1c)) (-1.3%; p < 0.0001), fasting glucose (-3.7 mmol/l; p < 0.0001), and within-patient fasting glucose variability (-0.5 mmol/l; p < 0.0001)."	( Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Dornhorst, A; Hansen, JB; Kozlovski, P; Looij, BJ; Lüddeke, HJ; Meneghini, L; Sreenan, S, 2008)	2.13

Excerpt	Reference	Relevance
" Six subjects discontinued the study, 2 as a result of adverse events (blood draw-related ecchymosis and hypoglycemia)."	( Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and Japanese american subjects. Jacobsen, LV; Jhee, SS; Leibowitz, MT; Lyness, WH; Rojas, PB; Zarotsky, V, 2004)	0.68
" The primary endpoint was incidence of serious adverse drug reactions (SADRs), including major hypoglycaemia."	( Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Dornhorst, A; Hansen, JB; Koenen, C; Landstedt-Hallin, L; Lüddeke, HJ; Sreenan, S; Tsur, A, 2007)	0.65
" The primary endpoint was serious adverse drug reactions (SADRs), including major hypoglycaemia."	( Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Ackermann, RW; Dornhorst, A; Gallwitz, B; Honka, M; Lüddeke, HJ; Meriläinen, M; Sreenan, S, 2008)	0.66
" Safety endpoints included adverse events (AEs) and hypoglycaemia."	( Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Hollander, P; Liutkus, JF; Raslova, K; Råstam, J; Skjøth, TV, 2011)	0.68
"Both insulin glargine and detemir improved HbA(1c) at short-term and proved to be safe and well tolerated in children and adolescents with type 1 DM."	( Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy. Dündar, BN; Dündar, N; Eren, E, 2009)	0.59
" Adverse event data (including hypoglycaemia) and glycaemic control were recorded before and 24 weeks following insulin initiation while patients continued routine clinical management."	( The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Caputo, S; Damci, T; Dzida, GJ; Ji, Q; Kaiser, M; Karnieli, E; Khunti, K; Liebl, A; Ligthelm, RJ; Meneghini, LF; Nazeri, A; Orozco-Beltran, D; Pan, C; Ross, SA; Svendsen, AL; Vora, J; Yale, JF, 2012)	0.64
" During the study, 27 patients experienced serious adverse drug reaction, severe hypoglycaemic events or both; and there were 31 episodes of severe hypoglycaemia in 21 patients."	( The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Caputo, S; Damci, T; Dzida, GJ; Ji, Q; Kaiser, M; Karnieli, E; Khunti, K; Liebl, A; Ligthelm, RJ; Meneghini, LF; Nazeri, A; Orozco-Beltran, D; Pan, C; Ross, SA; Svendsen, AL; Vora, J; Yale, JF, 2012)	0.64
"Addition of once-daily insulin detemir to patients with type 2 diabetes mellitus on OHA therapy resulted in few adverse events, significant improvements in glycaemic control, small reductions in weight and low rates of hypoglycaemia."	( The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Caputo, S; Damci, T; Dzida, GJ; Ji, Q; Kaiser, M; Karnieli, E; Khunti, K; Liebl, A; Ligthelm, RJ; Meneghini, LF; Nazeri, A; Orozco-Beltran, D; Pan, C; Ross, SA; Svendsen, AL; Vora, J; Yale, JF, 2012)	0.95
" Gastrointestinal-related and injection site-related adverse events occurred more frequently with EQW than with detemir."	( Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Adetunji, O; Davies, M; Heller, S; Sapin, H; Sreenan, S; Tahbaz, A; Vora, J, 2013)	0.64
" The primary outcome measure was the incidence of severe adverse drug reactions; just one major hypoglycemic event occurred in a patient in the ND stratum during the study and one patient was withdrawn due to injection-site reactions."	( A multicenter observational safety study in Swedish children and adolescents using insulin detemir for the treatment of type 1 diabetes. Carlsson, A; Forsander, G; Larsen, S; Ludvigsson, J; Ortqvist, E, 2013)	0.61
" The primary outcome was the incidence of serious adverse drug reactions including major hypoglycaemia over 24 weeks."	( Safety and effectiveness of insulin detemir in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study. Jain, AB; Khoo, CM; Mohamed, M; Soewondo, P; Sy, RA, 2013)	0.68
" The primary outcome was the incidence of serious adverse drug reactions (SADRs), including major hypoglycaemia."	( Safety and effectiveness of insulin analogues in type 2 diabetic patients from Algeria: a sub-analysis of the A₁chieve study. Arbouche, Z; Bachaoui, M; Dahaoui, A; Malek, R, 2013)	0.39
" The primary outcome was the evaluation of serious adverse drug reactions including major hypoglycaemic events."	( Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A₁chieve study. Ajdi, F; Belkhadir, J; Chraibi, A; El Ansari, N; Farouqi, A; Marouan, F, 2013)	0.39
" The primary outcome was the incidence of serious adverse drug reactions (SADRs), including major hypoglycaemic events."	( Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study. Belhadj, M; Dahaoui, A; Farouqi, A; Jamoussi, H, 2013)	0.39
"Once-daily insulin detemir therapy was safe and effective, and rates of hypoglycemia were low."	( Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice. Dzida, G; Ji, Q; Kaiser, M; Ligthelm, R; Meneghini, L; Nazeri, A; Orozco-Beltran, D; Pan, C; Ross, S; Svendsen, AL, 2014)	1.11
" Both treatments were well tolerated with comparable rates of adverse events."	( Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Danne, T; Deeb, L; Iotova, V; Kawamura, T; Kinduryte, O; Klingensmith, G; Ocampo Francisco, AM; Philotheou, A; Silverstein, J; Thalange, N; Tumini, S, 2015)	0.42
" Insulin is the most effective pharmacological treatment for controlling hyperglycemia during gestation and can limit adverse outcomes."	( The use of insulin detemir during pregnancy: a safety evaluation. Hod, M; Koren, R; Toledano, Y, 2015)	0.81
"Aspart, glargine, and detemir are safe treatment options for diabetes during pregnancy; these insulin analogs did not increase complications for the mothers or fetuses in our study."	( Safety of insulin analogs during pregnancy: a meta-analysis. Lv, S; Wang, J; Xu, Y, 2015)	0.42
" The primary endpoint was to assess the incidence of serious adverse drug reactions (SADRs) including in the specific major hypoglycemic events during 24 weeks of once-daily insulin detemir treatment."	( Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study. Caputo, S; Lastoria, G; Mannino, D; Maran, A; Morano, S; Nicoziani, P, 2015)	0.9
" Serious adverse events (SAEs) were recorded at 3 and 6 months."	( Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors. Gao, Y; Guo, X; Ji, J; Ji, L; Li, X; Zhang, H; Zhang, P; Zhang, T; Zhao, F; Zhu, D, 2017)	0.46
" There was no difference in overall severe or blood glucose-confirmed hypoglycaemic episodes or treatment-emergent adverse events between treatments."	( Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial. Birk Østerskov, A; Bode, BW; Franek, E; Graungaard, T; Mathieu, C; Philis-Tsimikas, A; Rose, L; Russell-Jones, D, 2018)	0.48
" This treatment strategy is an effective and safe alternative to a basal-bolus insulin regimen."	( A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study. Abreu, M; Adams-Huet, B; Dimachkie, P; Elhassan, A; Gunasekaran, U; Li, X; Lingvay, I; Meneghini, LF; Papacostea, O; Peicher, K; Pop, LM; Siddiqui, MS; Tumyan, A, 2019)	0.51
" The adverse drug reactions were rare and similar between the two groups."	( Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study. Gao, J; Guo, N; Han, Z; He, Z; Ji, J; Luo, X; Ma, Z; Mi, Y; Yang, Z; Zhao, H, 2020)	0.83
" Compared with NPH, IDet could control blood glucose and reached the targets faster and more effectively, thus reducing the number of insulin injections and the incidence of hypoglycemia in pregnant women without increasing adverse birth outcomes."	( Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study. Gao, J; Guo, N; Han, Z; He, Z; Ji, J; Luo, X; Ma, Z; Mi, Y; Yang, Z; Zhao, H, 2020)	0.83
"This study aimed to compare the rate of hypoglycemic events from all spontaneously reported adverse events (AEs) between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System (KAERS) database."	( Disproportionality analysis of spontaneously reported hypoglycemia events due to insulin use: A comparison between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System. Jeong, D; Kim, W; Shin, JY, 2021)	1.04
"We analyzed data on the reported hypoglycemia events retrieved from adverse drug reactions (ADR) on the use of different insulin types from 2016 to 2017 in the Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System Database (KIDS-KD)."	( Disproportionality analysis of spontaneously reported hypoglycemia events due to insulin use: A comparison between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System. Jeong, D; Kim, W; Shin, JY, 2021)	0.83
" More research should be conducted to reach a safe conclusion about the optimal insulin regimen for women with diabetes in pregnancy."	( Safety and efficacy of insulin detemir versus NPH in the treatment of diabetes during pregnancy: Systematic review and meta-analysis of randomized controlled trials. Athanasiadou, KI; Goulis, DG; Haidich, AB; Papakonstantinou, E; Paschou, SA; Stamatopoulos, T, 2022)	1.03

Excerpt	Reference	Relevance
" We investigated the pharmacokinetic and pharmacodynamic properties of insulin analogue NN304 (0."	( Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Brunner, GA; Ellmerer, M; Hirschberger, S; Krejs, GJ; Pieber, TR; Sendhofer, G; Siebenhofer, A; Søgaard, B; Wutte, A, 2000)	0.31
"This trial aimed to characterize for the first time the pharmacokinetic profile of insulin detemir, the novel soluble basal insulin analog, in children and adolescents compared with adults."	( Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Danne, T; Gall, MA; Lüpke, K; Von Schuetz, W; Walte, K, 2003)	1.99
"The mean pharmacokinetic profile of insulin detemir was similar across all three age-groups."	( Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Danne, T; Gall, MA; Lüpke, K; Von Schuetz, W; Walte, K, 2003)	2.04
" For pharmacokinetic evaluations, serial blood sampling was performed over a period of 30 hours after dosing."	( Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and Japanese american subjects. Jacobsen, LV; Jhee, SS; Leibowitz, MT; Lyness, WH; Rojas, PB; Zarotsky, V, 2004)	0.68
"To investigate the pharmacodynamic profile and duration of action for five subcutaneous doses of insulin detemir (0."	( A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Bodenlenz, M; Draeger, E; Endahl, LA; Görzer, E; Magnes, C; Pieber, TR; Plank, J; Regittnig, W; Sinner, F; Zdravkovic, M, 2005)	0.55
"This study shows that insulin detemir provides a flat and protracted pharmacodynamic profile."	( A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Bodenlenz, M; Draeger, E; Endahl, LA; Görzer, E; Magnes, C; Pieber, TR; Plank, J; Regittnig, W; Sinner, F; Zdravkovic, M, 2005)	0.64
" The two analogues are popularly perceived to differ from each other in their pharmacodynamic (PD) profiles, in particular with regard to 'flatness' and duration of action."	( Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Heise, T; Pieber, TR, 2007)	0.34
" Insulin aspart and insulin lispro have nearly identical pharmacokinetic and pharmacodynamic profiles and provide better postprandial glucose control and less hypoglycaemia (primarily nocturnal and severe hypoglycaemia in type 1 diabetes mellitus) than regular insulin."	( New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. Roach, P, 2008)	0.35
" This randomized, double-blind, crossover trial compared the within-subject variability of detemir and insulin glargine (glargine) in pharmacokinetic properties in children and adolescents with T1DM."	( Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Danne, T; Datz, N; Endahl, L; Fjording, MS; Haahr, H; Kordonouri, O; Nestoris, C; Westergaard, L, 2008)	1.79
"8 U/kg) and evaluate pharmacokinetic (PK) and pharmacodynamic (PD) dose responses of ILPS."	( Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Campaigne, BN; Hompesch, M; Jacober, SJ; Kollmeier, AP; Morrow, LA; Ocheltree, SM; Wondmagegnehu, ET, 2009)	0.56
"This pedagogical review illustrates the differences between pharmacokinetic (PK) and pharmacodynamic (PD) measures, using insulin therapy as the primary example."	( How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Arnolds, S; Heise, T; Kapitza, C; Kuglin, B, 2010)	0.36
" The aim was to directly compare the pharmacodynamic properties of the long-acting insulin analogues and NPH insulin after a single subcutaneous injection."	( Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans. Brock, B; Mengel, A; Moller, N; Nielsen, S; Rungby, J; Schmitz, O; Sørensen, LP; Vølund, A, 2010)	0.59
"In this experimental design, only minor pharmacodynamic differences were demonstrated between insulin detemir, insulin glargine and NPH insulin."	( Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans. Brock, B; Mengel, A; Moller, N; Nielsen, S; Rungby, J; Schmitz, O; Sørensen, LP; Vølund, A, 2010)	0.81
"To compare the pharmacokinetic (PK) [area under the curve (AUC₀(-)₂₄ (h), C(max))] and pharmacodynamic (PD) (AUC(GIR) ₀(-)₂₄ (h), GIR(max)) properties of single-dose insulin detemir in the presence or absence of steady-state liraglutide (1."	( Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Chang, D; Chatterjee, DJ; Guthrie, H; Hompesch, M; Morrow, L, 2011)	0.84
"To compare the pharmacodynamic properties of insulin detemir (detemir) and neutral protamine lispro (NPL) insulin using a euglycaemic glucose clamp."	( A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. Bock, G; Glettler, K; Koehler, G; Korsatko, S; Mader, JK; Olsen, KJ; Pieber, TR; Semlitsch, B; Wutte, A, 2013)	0.89
" Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs."	( A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. Bock, G; Glettler, K; Koehler, G; Korsatko, S; Mader, JK; Olsen, KJ; Pieber, TR; Semlitsch, B; Wutte, A, 2013)	0.64
"The pharmacodynamic characteristics of the basal insulin analogues insulin detemir (IDet) and insulin glargine (IGlar) have been examined extensively via euglycaemic clamp studies."	( Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Koehler, G; Korsatko, S; Mader, JK; Pieber, TR; Semlitsch, B; Treiber, G; Wutte, A, 2014)	0.64
"Pharmacokinetic and pharmacodynamic profiles of exogenous insulin may be affected by intrinsic factors, such as age, ethnicity/race, and hepatic and renal function."	( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus. Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014)	0.4
"The purpose of this study was to investigate whether the pharmacokinetic and pharmacodynamic responses to IDeg at steady state vary according to patient race/ethnicity."	( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus. Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014)	0.4
" Differences in pharmacokinetic and pharmacodynamic variables among groups were analyzed using an ANOVA with treatment period, an interaction between race/ethnicity, and treatment as fixed factors, subject as a random effect, and residual variance, depending on treatment."	( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus. Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014)	0.4
"The similar pharmacokinetic and pharmacodynamic responses to IDeg in 3 racial/ethnic groups of patients with type 2 diabetes mellitus suggest that the flat, stable, and ultralong pharmacokinetic and pharmacodynamic profiles of IDeg are preserved irrespective of race/ethnicity."	( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus. Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014)	0.4
"Despite their widespread use in this population, data on the pharmacodynamic (PD) properties of the insulin analogs detemir and glargine in severely obese patients with type 2 diabetes are lacking."	( Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial. Bilz, S; Falconnier, C; Flückiger, M; Keller, U; Meienberg, F; Puder, JJ, 2018)	0.48
" Model specific parameters are identified using data from a range of published clinical studies on the pharmacokinetic of insulin Detemir."	( A subcutaneous insulin pharmacokinetic model for insulin Detemir. Chase, JG; Knopp, JL; van Noorden, B, 2019)	0.98
"A first model of insulin Detemir including its unique albumin binding kinetics is derived and provisionally validated against clinical pharmacokinetic data."	( A subcutaneous insulin pharmacokinetic model for insulin Detemir. Chase, JG; Knopp, JL; van Noorden, B, 2019)	1.11

Excerpt	Reference	Relevance
"The aim of this trial was to evaluate the efficacy and safety of the combination of once-daily insulin detemir (IDet) and sitagliptin (SITA) versus SITA ± sulphonylurea (SU), both in combination with metformin (MET) in insulin-naive subjects."	( Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Hollander, P; Liutkus, JF; Raslova, K; Råstam, J; Skjøth, TV, 2011)	0.9
"The combination of once-daily IDet with SITA showed a clinically and significantly better improvement in glycaemic control than SITA in combination with or without SUs."	( Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Hollander, P; Liutkus, JF; Raslova, K; Råstam, J; Skjøth, TV, 2011)	0.68
" The Italian arm of the Solve™ Study aimed to evaluate the safety and the effectiveness of once-daily insulin detemir in combination with OAD agents for the treatment of patients with T2DM in the Italian outpatient specialist setting."	( Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study. Caputo, S; Lastoria, G; Mannino, D; Maran, A; Morano, S; Nicoziani, P, 2015)	0.93

Excerpt	Reference	Relevance
"Manufacturers of insulin products for diabetes therapy have long sought ways to modify the absorption rate of exogenously administered insulins in an effort to better reproduce the naturally occurring pharmacokinetics of endogenous insulin secretion."	( Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Heise, T; Mathieu, C, 2017)	0.46

Excerpt	Relevance	Reference
"Injection of NN304 at different doses resulted in an increase in total NN304 concentration in a linear dose-response effect and a more even metabolic effect than NPH-insulin."	( Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Heinemann, L; Heise, T; Hirschberger, S; Loftager, M; Sinha, K; Weyer, C, 1999)	0.3
"001), suggesting a clear dose-response relationship for both NPH insulin and NN304."	( Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Brunner, GA; Ellmerer, M; Hirschberger, S; Krejs, GJ; Pieber, TR; Sendhofer, G; Siebenhofer, A; Søgaard, B; Wutte, A, 2000)	0.31
" Other drawbacks include inter- and intra-patient variability that compromises dosing reproducibility and unsuitability for single daily dosing."	( A review of basal insulins. Barnett, AH, 2003)	0.32
" There was a linear dose-response relationship between the three ascending insulin detemir doses and serum insulin detemir AUC values for both the Japanese and Caucasian subjects."	( Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and Japanese american subjects. Jacobsen, LV; Jhee, SS; Leibowitz, MT; Lyness, WH; Rojas, PB; Zarotsky, V, 2004)	0.91
"To evaluate the time-action profiles and the dose-response relationship of the long-acting insulin analogues insulin detemir (IDet) and NPH insulin (NPH) in type 2 diabetic patients belonging to different ethnic groups."	( Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Elbroend, B; Endahl, L; Haahr, H; Heinemann, L; Heise, T; Hompesch, M; Troupin, B, 2006)	0.86
"These results confirm a linear dose-response relationship of IDet, without any relevant differences between ethnic groups."	( Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Elbroend, B; Endahl, L; Haahr, H; Heinemann, L; Heise, T; Hompesch, M; Troupin, B, 2006)	0.64
"The pharmacology, pharmacokinetics, efficacy and tolerability, safety, drug interactions, dosage and administration, cost, and place in therapy of insulin detemir are reviewed."	( Insulin detemir: a long-acting insulin product. Jones, MC; Patel, M, 2006)	1.98
" In most trials, patients were randomized to receive insulin on three different dosing schedules: basal insulin twice daily before breakfast and at bedtime, basal insulin at 12-hour intervals, or basal insulin before breakfast and dinner."	( Insulin detemir: a long-acting insulin product. Jones, MC; Patel, M, 2006)	1.78
"8 dosing units (DU) (1 DU corresponds to 6 nmol NN344) per kilogram of body weight."	( Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Damholt, B; Endahl, L; Heise, T; Klein, O; Lynge, J; Nosek, L, 2007)	0.61
" The information provided is tailored to diabetes educators and includes mechanism of action, pharmacokinetics, drug interactions, clinical trials, dosage and administration guidelines, side effects, and educational pearls for each insulin discussed."	( Update in the pharmacologic treatment of diabetes: focus on insulin detemir, insulin glulisine, and inhaled dry powdered insulin. Campbell, RK; Iltz, JL; Odegard, PS; Setter, SM, )	0.37
" Attention was paid to dosing schedules and 24-h glycaemic profiles."	( Refining basal insulin therapy: what have we learned in the age of analogues? Devries, JH; Nattrass, M; Pieber, TR, 2007)	0.34
" Morning administration tends to require higher dosing than evening administration."	( Refining basal insulin therapy: what have we learned in the age of analogues? Devries, JH; Nattrass, M; Pieber, TR, 2007)	0.34
"Forty-three case reports of patients with type 2 diabetes who were treated with insulin detemir (Levemir, Novo Nordisk A/S, Bagsvaerd, Denmark) were collected from doctors' offices for the purpose of analyzing 4 parameters: (1) effectiveness of glycemic control (fasting blood glucose [FBG] readings and glycosylated hemoglobin [A1C]); (2) tolerability (hypoglycemic episodes and weight gain); (3) dosing regimen; and (4) treatment discontinuations."	( Levemir Early Clinical Experience Case Series. Mayerson, AB, 2007)	0.57
"The Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation 303 (PREDICTIVE 303) Study (n = 5604) evaluated the effectiveness of insulin detemir, a long-acting basal insulin analogue, using a simplified patient self-adjusted dosing algorithm (303 Algorithm group) compared with standard-of-care physician-driven adjustments (Standard-of-care group) in a predominantly primary care setting, over a period of 6 months."	( The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study. Koenen, C; Meneghini, L; Selam, JL; Weng, W, 2007)	0.76
" With detemir, 45% of participants completed the study on once daily dosing and 55% on twice daily dosing, with no difference in HbA(1c)."	( A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Davies, M; Home, PD; Koenen, C; Larsen, J; Rosenstock, J; Schernthaner, G, 2008)	0.59
"Basal bolus insulin dosing (BBD) may be defined as the physiological replacement of basal and bolus insulin to achieve near normal glycemia without hypoglycemia and loss of life quality."	( Basal bolus dosing: a clinical experience. Armstrong, DU; King, AB, 2005)	0.33
" The results of both glucose clamp studies and clinical trials support initiation of detemir at a once-daily dosing regimen."	( An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update). Philis-Tsimikas, A, 2008)	0.65
"4 U/kg of detemir and glargine was injected subcutaneously 24 h apart at each of two dosing visits."	( Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Danne, T; Datz, N; Endahl, L; Fjording, MS; Haahr, H; Kordonouri, O; Nestoris, C; Westergaard, L, 2008)	1.79
"Once-daily dosing with insulin detemir and insulin glargine were compared in a double-blind, randomised, crossover study in type 2 diabetes subjects previously treated with other antihyperglycaemic medications."	( Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. King, AB, 2009)	1.05
"The aim was to compare clinical outcomes by different dosing frequencies of insulin detemir (detemir) used over 52 weeks in various regimens."	( Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE. Fontaine, P; Gin, H; Hanaire, H; Marre, M; Pinget, M; Robert, JJ; Thivolet, C; Venkatanarasimhachar, S, 2009)	0.98
" In each cohort, data were stratified according to detemir dosing frequency at the beginning and end of 52 weeks: once daily (o."	( Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE. Fontaine, P; Gin, H; Hanaire, H; Marre, M; Pinget, M; Robert, JJ; Thivolet, C; Venkatanarasimhachar, S, 2009)	0.76
" We found no dose-response relationship between end-of-study insulin dose and hypoglycaemia or weight gain."	( Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes. DeVries, JH; Swinnen, SGHA, 2009)	0.35
" These results potentially support once-daily dosing of ILPS in T2DM."	( Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Campaigne, BN; Hompesch, M; Jacober, SJ; Kollmeier, AP; Morrow, LA; Ocheltree, SM; Wondmagegnehu, ET, 2009)	0.56
" In this study, injection force requirements and dosage scale displays were evaluated for NovoPen 3 and NovoPen 4 (both from Novo Nordisk A/S, Copenhagen, Denmark)."	( A comparison of injection force and dosage scale size between NovoPen 3 and NovoPen 4. Donsmark, M; Herold, L; Kristensen, CM, 2009)	0.35
" To compare dosage scale displays, digital images of multiple settings were made, and the total inked areas of digits were converted to mm(2)."	( A comparison of injection force and dosage scale size between NovoPen 3 and NovoPen 4. Donsmark, M; Herold, L; Kristensen, CM, 2009)	0.35
" A higher dosage was chosen for detemir to compensate for its delay in impact relative to human insulin and to elicit similar systemic effects."	( Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Born, J; Hallschmid, M; Jauch-Chara, K; Kern, W; Korn, O; Mölle, M; Rasch, B; Schultes, B, 2010)	0.67
" Further, the mean dosage to achieve this glucose goal was the same with both insulins."	( No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring. King, AB, 2010)	0.64
" Previous studies have demonstrated noninferiority of insulin detemir, dosed once or twice daily, and insulin glargine, dosed once daily."	( An analysis of dosing equivalence of insulin detemir and insulin glargine: more evidence? True, MW, 2010)	0.88
" More ILPS patients used twice-daily dosing (59% vs."	( A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes. Dharmalingam, M; Fogelfeld, L; Jacober, S; Jones, C; Robling, K; Swanson, D, 2010)	0.58
"To compare the properties of insulin detemir with human insulin or insulin aspart in various in vitro and in vivo experiments, thereby highlighting the importance of performing dose-response studies when investigating insulin analogues, in this study specifically insulin detemir."	( Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Bouman, SD; Brand, CL; Jonassen, I; Kurtzhals, P; Nishimura, E; Ribel, U; Stidsen, CE; Sturis, J; Sørensen, AR, 2010)	2.09
" The hyperinsulinaemic euglycaemic clamp technique in rats is used to establish dose-response curves for multiple metabolic endpoints and to investigate the effects of the simultaneous presence of insulin detemir and human insulin."	( Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Bouman, SD; Brand, CL; Jonassen, I; Kurtzhals, P; Nishimura, E; Ribel, U; Stidsen, CE; Sturis, J; Sørensen, AR, 2010)	1.99
"Both in vitro and in vivo, insulin detemir shows full efficacy and right-shifted parallel dose-response curves compared with human insulin."	( Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Bouman, SD; Brand, CL; Jonassen, I; Kurtzhals, P; Nishimura, E; Ribel, U; Stidsen, CE; Sturis, J; Sørensen, AR, 2010)	2.1
" The fact that the potency estimates are method-dependent emphasizes the importance of establishing full dose-response relationships when characterizing insulin detemir."	( Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Bouman, SD; Brand, CL; Jonassen, I; Kurtzhals, P; Nishimura, E; Ribel, U; Stidsen, CE; Sturis, J; Sørensen, AR, 2010)	2
" Furthermore, intensive glycemic control was achieved with insulin detemir in insulin dependent diabetic dogs, using a lower dosage than NPH insulin and insulin glargine therapeutic doses."	( Time-action profiles of insulin detemir in normal and diabetic dogs. Arai, T; Ishioka, K; Kurishima, M; Lee, P; Makino, Y; Miki, Y; Mimura, K; Mizutani, H; Mori, A; Nozawa, S; Oda, H; Saeki, K; Sako, T, 2011)	0.92
"A pooled analysis of randomized controlled trials of individuals with type 2 diabetes mellitus (T2DM) was conducted to compare dosing and impact of two basal insulin analogs, insulin glargine (glargine) and insulin detemir (detemir), on weight and hemoglobin A1c (A1c)."	( Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Admane, K; Dailey, G; Mercier, F; Owens, D, 2010)	0.76
" There was no loss of glycemic control by the end of the once-daily dosing interval."	( Comparison of 3 algorithms for Basal insulin in transitioning from intravenous to subcutaneous insulin in stable patients after cardiothoracic surgery. Dungan, K; Hall, C; Osei, K; Schuster, D, )	0.13
" After 12 weeks of basal insulin detemir dosage optimization, participants with a hemoglobin A1c level of 7% or greater entered three 12-week treatment periods with stepwise addition of a first insulin aspart bolus, then a second, and then a third, if hemoglobin A1c remained at 7% or greater after 12 and 24 weeks of treatment, respectively."	( Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Hermansen, K; Kumar, S; Meneghini, L; Mersebach, H; Svendsen, AL, )	0.64
" Insulin glargine was dosed once-daily in the evening."	( Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Devries, JH; Hoekstra, JB; Holleman, F; Simon, AC; Swinnen, SG, 2011)	1.81
" This was unaffected by adjustment for initial dosing group."	( Differential response between diabetes and stress-induced hyperglycaemia to algorithmic use of detemir and flexible mealtime aspart among stable postcardiac surgery patients requiring intravenous insulin. Dungan, K; Hall, C; Osei, K; Schuster, D, 2011)	0.37
" Insulin dosage was titrated according to fasting capillary blood glucose levels, and treatment was stopped after 2 weeks."	( Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment. Deng, H; Li, X; Lu, H; Mu, P; Wang, M; Zeng, L, 2012)	0.38
" Incomplete resuspension and precipitation appear to be important issues with regard to unpredictability in this action, while an inadequate duration of action relative to the dosing interval results in a fluctuating action profile."	( Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Heise, T; Vora, J, 2013)	0.39
" During the first 9 months, the insulin dosage to reach the postprandial blood glucose <140 mg/dl, were significantly lower in the IA-group, but approached the following the RHI-group without significant changes after 24 months."	( Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus. Dette, H; Herrmann, BL; Huptas, M; Kasser, C; Keuthage, W; Klute, A, 2013)	0.62
" The importance of patient education in overcoming barriers to insulin is discussed, as well as the choice of available basal insulins and the necessity to optimize basal insulin dosage by self-titration."	( Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. Philis-Tsimikas, A, 2013)	0.39
"To review the available evidence regarding dosing conversion between glargine and detemir in an effort to assist clinicians in performing dosing conversion."	( Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? McFarland, MS; Wallace, JL; Wallace, JP, 2014)	0.4
"All English-language clinical trials were reviewed for inclusion of dosing and/or pharmacokinetic data."	( Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? McFarland, MS; Wallace, JL; Wallace, JP, 2014)	0.4
"A total of 7 large (n ≥ 258) randomized controlled trials (RCTs) comparing glargine and detemir in patients with type 1 and 2 diabetes had dosing equivalency data available."	( Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? McFarland, MS; Wallace, JL; Wallace, JP, 2014)	0.4
" Patients were allocated randomly to a sequence of 2 treatment periods, separated by a 7- to 21-day washout period, with once-daily IDeg or insulin detemir dosing for 6 days at a predefined fixed dose level (0."	( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus. Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014)	0.6
"The strategies that aim at preventing diabetic retinopathy by treating T2DM patients with long-acting insulin analogues remain further prospective studies with longer follow-up period to validate our observations within an appropriate dosage range and to further evaluate the safety of long-acting insulin analogues on reducing the progression of diabetic retinopathy."	( Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study. Lai, MS; Lin, JC; Shau, WY, 2014)	0.4
" Significant differences were observed between the basal insulin groups for glycated hemoglobin level and dosing frequency."	( Use of basal insulin and the associated clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus: a retrospective chart review study. Davis, KL; Kilpatrick, BS; Meyers, JL; Pandya, N; Wei, W, 2014)	0.4
" Differences in glycated hemoglobin and dosing frequencies between types of basal insulin warrant further comparative effectiveness studies."	( Use of basal insulin and the associated clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus: a retrospective chart review study. Davis, KL; Kilpatrick, BS; Meyers, JL; Pandya, N; Wei, W, 2014)	0.4
" Insulin dose (intervention) was 60% of the usual, of this 40% was dosed as Levemir at sunrise and 60% as NovoMix 70 before dinner."	( Effect of a new insulin treatment regimen on glycaemic control and quality of life of Muslim patients with type 2 diabetes mellitus during Ramadan fast - an open label, controlled, multicentre, cluster randomised study. Maor, Y; Shehadeh, N, 2015)	0.42
" Indeed, NPH insulin remains widely used today despite a frequent need for a twice-daily dosing and a relatively high incidence of hypoglycaemia."	( Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Heise, T; Mathieu, C, 2017)	0.46
"A clear dose-response relationship can be demonstrated for both insulin analogs, even at very high doses in severely obese patients with type 2 diabetes."	( Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial. Bilz, S; Falconnier, C; Flückiger, M; Keller, U; Meienberg, F; Puder, JJ, 2018)	0.48
"Medical records were retrospectively analyzed to investigate the effect of a hospital formulary change at a semi-urban underserved hospital that substituted detemir for glargine on a 1:1 dosing basis."	( Detemir vs Glargine: Comparison of Inpatient Glycemic Control. Avanesyan, A; Cade, K; Capson, J, 2019)	0.51
" Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir."	( Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. Cheng, AYY; Patel, DK; Reid, TS; Wyne, K, 2019)	0.68
"In patients with HbA1c ≥10% treatment with GLP1RA plus basal insulin, compared with basal-bolus insulin, resulted in better glycaemic control and body weight, lower insulin dosage and hypoglycaemia, and improved quality of life."	( A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study. Abreu, M; Adams-Huet, B; Dimachkie, P; Elhassan, A; Gunasekaran, U; Li, X; Lingvay, I; Meneghini, LF; Papacostea, O; Peicher, K; Pop, LM; Siddiqui, MS; Tumyan, A, 2019)	0.51
" Thus, there is a strong potential motivation to develop models of long-acting insulin analogues to enable safe, effective use in model-based dosing systems."	( A subcutaneous insulin pharmacokinetic model for insulin Detemir. Chase, JG; Knopp, JL; van Noorden, B, 2019)	0.77
" We present results from 4 nonclinical rat studies evaluating effects of repeated dosing with insulin detemir (≤26 weeks) or degludec (52 weeks) in mammary glands."	( Evaluation of Cell Proliferation in Rat Mammary Glands Is Not Predictive of the Carcinogenic Potential of Insulin In Vivo. Brinck, PR; Jensen, VFH; Mølck, AM; Nowak, J; Sjögren, I; Thorup, I, )	0.35
" Clinical evaluations occurred on days 7 to 14, day 30, and then every 60 to 90 days, and dosage adjustments of detemir occurred as needed to control glycemia."	( Detemir improves diabetic regulation in poorly controlled diabetic dogs with concurrent diseases. Ford, SL; Harris-Samson, AR; Rand, J, 2023)	0.91
"The mean, peak, nadir, morning, and evening preinsulin daily blood glucose concentrations were significantly lower after dosing with detemir for 1, 3, or 6 months and during the last month of treatment compared to the final month of treatment with intermediate-acting insulin."	( Detemir improves diabetic regulation in poorly controlled diabetic dogs with concurrent diseases. Ford, SL; Harris-Samson, AR; Rand, J, 2023)	0.91

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	6 (1.08)	18.2507
2000's	192 (34.47)	29.6817
2010's	322 (57.81)	24.3611
2020's	37 (6.64)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	172 (29.40%)	5.53%
Reviews	129 (22.05%)	6.00%
Case Studies	27 (4.62%)	4.05%
Observational	29 (4.96%)	0.25%
Other	228 (38.97%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (179)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of 50-week Treatment With Stepwise Insulin Intensification of Basal-bolus Insulin Analogues (Insulin Detemir and Aspart) or Biphasic Insulin Aspart 30 (NovoMix 30) All in Combination With Fixed Dose of Metformin on Glycaemic Control (Measured as Hb [NCT01068652]	Phase 4	403 participants (Actual)	Interventional	2010-03-31	Completed
Effects of INsulin dEtemiR and Neutral protaminE Hagedorn (NPH) Insulin on BRain glucOse Metabolism: a Study in Persons With Type 1 Diabetes [NCT00626080]		40 participants (Anticipated)	Interventional	2009-01-31	Completed
A Multi-centre, Open-labeled, Randomized, Parallel Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After 26 Weeks Treatment With Insulin Detemir Once Daily Versus Insulin NPH Once Daily [NCT01310452]		50 participants (Anticipated)	Interventional	2011-01-31	Active, not recruiting
Evaluation of Insulin Detemir in Combination With OADs in Type 2 Diabetes Mellitus [NCT00592527]	Phase 3	132 participants (Actual)	Interventional	2004-04-30	Completed
Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus [NCT00655200]		2,286 participants (Actual)	Observational	2008-02-29	Completed
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised [NCT00322257]	Phase 3	596 participants (Actual)	Interventional	2006-05-01	Terminated(stopped due to See termination reason in detailed description)
A Trial Comparing the Effect and Safety of Insulin Degludec Versus Insulin Detemir, Both in Combination With Insulin Aspart, in the Treatment of Pregnant Women With Type 1 Diabetes [NCT03377699]	Phase 3	225 participants (Actual)	Interventional	2017-11-22	Completed
A Comparison of Two Initial Dosing Formulas for Basal Insulin in Type 2 Diabetes Mellitus [NCT01377155]		20 participants (Actual)	Interventional	2011-06-30	Completed
Retrospective Cohort Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine [NCT03960814]		12,847 participants (Actual)	Observational	2019-05-21	Completed
Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus [NCT00706017]		2,282 participants (Actual)	Observational	2007-09-30	Completed
"Making an ObeseBrain(and Body)Lean: Insulin Detemir,Monoamines,and Reward" [NCT01239550]		240 participants (Anticipated)	Interventional	2011-04-30	Active, not recruiting
A Trial Investigating the Pharmacodynamic Properties of NN1250 in Japanese Subjects With Type 1 Diabetes [NCT01135927]	Phase 1	22 participants (Actual)	Interventional	2010-06-30	Completed
Comparison of Two Titration Programs of Adding Insulin Detemir to Oral Antidiabetic Drugs in Poorly Controlled Type 2 Diabetes Patients [NCT01281605]		181 participants (Actual)	Interventional	2011-01-31	Completed
Observational Study of Glycaemic Control in Type 2 Diabetic Patients Uncontrolled on Oral Antidiabetic Agents and Starting With Once Daily Levemir® (Insulin Detemir) - 24 Weeks, Prospective, Multicentre Observational Study in Hungary [NCT00865397]		1,032 participants (Actual)	Observational	2009-02-28	Completed
NN1250-3585: A Trial Investigating the Efficacy and Safety of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen / NN1250-3725: An Extension Trial to NN1250-3585 Investigating Safety and Efficac [NCT01074268]	Phase 3	456 participants (Actual)	Interventional	2010-02-28	Completed
A Phase 2 Open Label Randomized Controlled Trial Determir Vs Neutral Protamine Hagedorn (NPH) In Pregnant Women: DETERMINE Study [NCT05124457]	Phase 2	336 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes [NCT00998335]	Phase 4	30 participants (Actual)	Interventional	2007-06-30	Completed
Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulphonylurea [NCT01003184]	Phase 3	222 participants (Actual)	Interventional	2009-10-31	Completed
Efficacy and Safety of Glycaemic Control of Levemir® or Insulatard® in Patients With Type 2 Diabetes [NCT00715351]		342 participants (Actual)	Observational	2007-05-31	Completed
A 48-week, Randomised, Multi-centre, Openlabelled, Parallel-group Trial to Compare the Efficacy and the Safety of NN304 (Insulin Detemir) and NPH Human Insulin in Subjects With Insulin Requiring Diabetes Mellitus on a Basal-bolus Regimen [NCT00604344]	Phase 3	401 participants (Actual)	Interventional	2003-04-30	Completed
Randomized, Long-Term Study About the Effects of Analogue Versus Human Insulin Based Regimens (Insulin Detemir and Aspart Versus NPH- and Regular Human Insulin) on Metabolic Control and Myocardial Function in People With Type 2 Diabetes. [NCT00747409]	Phase 4	120 participants (Anticipated)	Interventional	2004-07-31	Active, not recruiting
Evaluation of Glycaemic Control After Initiation of Levemir® in Patients With Type 2 Diabetes Mellitus and Time Period Between Diagnosis of Type 2 Diabetes Mellitus and Insulin Initiation. [NCT00793273]		1,074 participants (Actual)	Observational	2008-11-30	Completed
A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial to Compare the Pharmacodynamic Effects of Single Doses of Insulin Detemir and Neutral Protamin Lispro (NPL) Insulin in Subjects With Type 1 Diabetes [NCT00810589]	Phase 1	30 participants (Actual)	Interventional	2008-11-30	Completed
A Multicentre, Open Label, Observational 24-week Study to Evaluate Safety of Initiating Insulin Therapy With Levemir® (Insulin Detemir) Once-daily in Oral Antidiabetic Drug-treated Patients With Type 2 Diabetes [NCT00825643]		18,481 participants (Actual)	Observational	2008-04-30	Completed
Insulin Detemir Co-administered With Liraglutide: An Open Label Trial to Assess Insulin Detemir and Liraglutide Pharmacokinetics and Pharmacodynamics Following Liraglutide Therapy in Subjects With Type 2 Diabetes [NCT00873223]	Phase 1	33 participants (Actual)	Interventional	2009-03-31	Completed
The Metabolic and Glycaemic Effects of a Combined Basal-Bolus Insulin Reduction And Carbohydrate Feeding Strategy For Evening Exercise in Type 1 Diabetes Mellitus [NCT02204839]		10 participants (Actual)	Interventional	2014-01-31	Completed
Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment [NCT02048189]	Phase 4	60 participants (Anticipated)	Interventional	2012-03-31	Recruiting
A Six Month, Multi-centre, Open-label, Parallel Efficacy and Safety Comparison of Insulin Detemir and NPH Insulin in Subjects With Type 1 Diabetes on a Basal-bolus Regimen. [NCT03220425]	Phase 3	752 participants (Actual)	Interventional	2001-02-01	Completed
A Randomised, Three-period Crossover Trial in Healthy Subjects Investigating the Relationship Between the Pharmacodynamic Steady State and the Pharmacokinetic Steady State in the Interstitial Fluid Following iv Infusion of Insulin Detemir and Human Insuli [NCT02162407]	Phase 1	13 participants (Actual)	Interventional	1999-10-31	Completed
Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Detemir) in Basal-Bolus Therapy for Patients With Type 1 Diabetes [NCT00487240]	Phase 3	387 participants (Actual)	Interventional	2007-06-30	Completed
Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus [NCT00709475]		747 participants (Actual)	Observational	2008-05-31	Completed
A 32-week National, Single-centre, Open-labelled, Randomised, Crossover Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes [NCT00509925]	Phase 4	23 participants (Actual)	Interventional	2007-07-31	Terminated(stopped due to See detailed description)
Evaluation on Safety of Self-titration in Insulin naïve People With Type 2 Diabetes Treated With Levemir® (Insulin Detemir) and Oral Antidiabetic Agents [NCT00740519]		882 participants (Actual)	Observational	2008-09-30	Completed
A 12-months Multi-national, Multi-centre, Double Blind, Randomised, Parallel Safety and Efficacy Comparison of Insulin Detemir Produced by the Current Process and Insulin Detemir Produced by the NN729 Process in Subjects With Type 1 Diabetes on a Basal-bo [NCT00447382]	Phase 3	330 participants (Actual)	Interventional	2007-03-31	Completed
Prospective, Multicentre, Open Label, Non-controlled, 24-week Observation in Type 2 Diabetics Using Once Daily Levemir® (Insulin Detemir) as Part of Their ITT Regimen [NCT00806897]		74 participants (Actual)	Observational	2009-01-31	Completed
A Randomised, Parallel-group, Open-labelled, Multinational Trial Comparing the Efficacy and Safety of Insulin Detemir (Levemir®) Versus Human Insulin (NPH Insulin), Used in Combination With Insulin Aspart as Bolus Insulin, in the Treatment of Pregnant Wom [NCT00474045]	Phase 3	470 participants (Actual)	Interventional	2007-05-31	Completed
A Phase 4, Randomized, Open Label, Parallel Group, Multicenter Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes [NCT00467649]	Phase 4	112 participants (Actual)	Interventional	2007-05-31	Completed
Comparison of Efficacy and the Safety of Insulin Detemir and Insulin NPH as add-on to Current OHA Therapy in Subjects With type2 Diabetes Mellitus [NCT00604253]	Phase 3	362 participants (Actual)	Interventional	2003-12-31	Completed
RAndomized SubCutaneous Insulin in INpatients (RASCIN) Trial: Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin [NCT00906529]	Phase 4	0 participants (Actual)	Interventional	2009-05-31	Withdrawn
Effects of Insulin Detemir Versus Regular Insulin (Actrapid) on Hormonal Counterregulation, Cognitive Function and Symptom Perception During Hypoglycemia [NCT00490893]	Phase 4	12 participants (Actual)	Interventional	2006-03-31	Terminated
Safety and Efficacy of Insulin Detemir (Levemir® FlexPen®) in Patients With Diabetes Mellitus [NCT00670683]		797 participants (Actual)	Observational	2007-07-31	Completed
Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 1 or Type 2 Diabetes Mellitus [NCT00655044]		3,637 participants (Actual)	Observational	2007-05-31	Completed
Evaluation on Glycaemic Control and Weight Change of Once Daily Levemir® (Insulin Detemir) in Type 2 Diabetes Mellitus Treated by an Intensive Insulin Treatment (ICT) [NCT00657930]		2,289 participants (Actual)	Observational	2008-03-31	Completed
Insulin Detemir (Levemir®) Versus Isophane (NPH) Insulin (Protaphane®) in Combination With Oral Antidiabetic Agents (OAD) in Patients With Diabetes Mellitus Type 2 Comparing Treatment Satisfaction, Diabetes-related and General Health-related Quality of Li [NCT00665808]		8,125 participants (Actual)	Observational	2007-10-31	Completed
Observational Study on Evaluation of Glycaemic Control in Patients Using a Modern Insulin - NovoRapid® (Insulin Aspart), NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus [NCT00670722]		6,500 participants (Actual)	Observational	2008-01-31	Completed
Observational Safety and Efficacy Study in Subjects Using Insulin for the Treatment of Type 2 Diabetes Mellitus Failing on Oral Anti-diabetic Agents [NCT00715780]		1,667 participants (Actual)	Observational	2008-06-30	Completed
Cystic Fibrosis - Insulin Deficiency, Early Action [NCT01100892]	Phase 3	100 participants (Anticipated)	Interventional	2010-12-31	Completed
Role of Insulin Aspart and Detemir to Assess Glucose Excursion in Children With Type 1 Diabetes [NCT00564395]	Phase 4	18 participants (Actual)	Interventional	2007-08-31	Completed
Effects of Different Insulin Regimens on Artery Compliance, Endothelium Function and Autonomic Cardiac Function in Patients With Poorly Controlled Type 2 Diabetes: a Pilot Study [NCT01022658]		42 participants (Actual)	Interventional	2010-01-31	Completed
A 52-Week, Multinational, Multi-Centre, Open-Labelled Extension Trial of Insulin Detemir in Children and Adolescents 3-17 Years With Type 1 Diabetes on a Basal-Bolus Regimen With Insulin Aspart as Bolus Insulin [NCT00623194]	Phase 3	146 participants (Actual)	Interventional	2008-02-29	Completed
Observational Study on Evaluation of Glycaemic Control in Patients Using Levemir® (Insulin Detemir) as Initiation Insulin Therapy by Levemir® (Insulin Detemir) Administered Once Daily as the Treatment for Type 2 Diabetes Mellitus. [NCT00687284]		2,188 participants (Actual)	Observational	2008-02-29	Completed
Assessment of Safety and Efficacy of Levemir® (Insulin Detemir) Treatment for Insulin Naive Patients With Type 2 Diabetes Mellitus [NCT00700830]		1,976 participants (Actual)	Observational	2008-01-31	Completed
Effects of Optimized Glycemic Control Achieved With add-on Basal Insulin Therapy on Indexes of Endothelial Damage and Regeneration in Type 2 Diabetic Patients With Macroangiopathy. A Randomized Cross-over Trial Comparing Detemir vs Glargine [NCT00699686]	Phase 4	50 participants (Anticipated)	Interventional	2008-05-31	Completed
Safety of Levemir® (Insulin Detemir) Treatment in Children and Adolescents With Type 1 Diabetes (PREDICTIVE™ - Youth) [NCT00704574]		159 participants (Actual)	Observational	2008-01-31	Completed
A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia [NCT00665093]		1,569 participants (Actual)	Observational	2007-05-31	Completed
Effect of Detemir and Sitagliptin on Blood Glucose Control in Subjects With Type 2 Diabetes Mellitus [NCT00789191]	Phase 3	222 participants (Actual)	Interventional	2008-11-30	Completed
An Efficacy and Safety Comparison of Insulin Detemir vs. NPH Insulin in Children and Adolescents Diagnosed With Type 1 Diabetes [NCT00435019]	Phase 3	348 participants (Actual)	Interventional	2007-02-28	Completed
Safety of Levemir® (Insulin Detemir) Treatment in Patients With Type 2 Diabetes [NCT00735501]		314 participants (Actual)	Observational	2008-03-31	Completed
Efficacy and Safety Study of Levemir® (Insulin Detemir) to Treat Type 1 and 2 Diabetes Mellitus [NCT00738153]		798 participants (Actual)	Observational	2008-06-30	Completed
A Multi-centre, Open-labelled, Randomised, Two-group Parallel Trial Comparing the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After 26 Weeks of Treatment With Insulin Detemir Once Daily Versus Insulin NPH Once Daily, B [NCT00795600]	Phase 4	60 participants (Actual)	Interventional	2009-04-30	Completed
Use of Levemir® Improves Metabolic and Clinical Status in CFRD [NCT00639626]	Phase 2/Phase 3	6 participants (Actual)	Interventional	2008-08-31	Terminated(stopped due to PI left the institution)
A Multicentre, Open-label, Nonrandomised, Non-interventional, Observational Study to Compare Safety and Effectiveness of Biphasic Insulin Aspart 30 (NovoMix 30) and Insulin Detemir (Levemir) for the Treatment of Diabetes Mellitus [NCT00789711]		3,131 participants (Actual)	Observational	2008-11-30	Completed
The Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-diabetic Medication. A 24-week, International, Prospective, Multi-centre, Open-labelled, Non-interventional Stu [NCT00869908]		66,726 participants (Actual)	Observational	2008-11-30	Completed
Efficacy and Safety Study in Subjects Using Levemir® (Insulin Detemir), NovoMix®30 (Biphasic Insulin Aspart 30) and/or NovoRapid® (Insulin Aspart) for the Treatment of Type 1 or Type 2 Diabetes Mellitus [NCT00698269]		5,926 participants (Actual)	Observational	2008-02-29	Completed
Doubleblind, Randomised, Single Centre Investigator Sponsored Study of Applications Site Reactions After Deep and Superficial Subcutaneous and Intradermal Injection of Insulin Detemir and Saline in Subjects With Diabetes Mellitus [NCT00607737]	Phase 4	40 participants (Actual)	Interventional	2008-01-31	Completed
Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir and Insulin Glargine [NCT00656422]	Phase 3	66 participants (Actual)	Interventional	2007-11-30	Terminated
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insuli [NCT01165684]	Phase 4	401 participants (Actual)	Interventional	2010-10-31	Completed
Effects of Basal Insulin Analogue Detemir on Body Composition, Epicardial Fat and Energy Metabolism [NCT00862875]	Phase 4	42 participants (Actual)	Interventional	2009-03-31	Completed
Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention and Weight in Type 2 Diabetic Patients [NCT00742976]	Phase 4	24 participants (Actual)	Interventional	2008-06-30	Completed
A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoRapid® (Insulin Aspart) and Levemir® (Insulin Detemir) in a Basal-bolus Regimen for Treatment of Type 1 Diabetes Mellitus in Romania [NCT00873639]		417 participants (Actual)	Observational	2009-04-30	Completed
Impact of Insulin (I.)Glargine Compared to NPH I. and to I. Detemir in Combination With Metformin on Prandial ß-cell Function and Overall Metabolic Control in Type 2 Diabetic Patients With Insufficient Metabolic Control During OAD Treatment [NCT00941148]	Phase 4	30 participants (Actual)	Interventional	2008-04-30	Completed
Observational Study Evaluating the Body Weight Progress During the Treatment With Insulin Detemir (Levemir®) in Type 2 Patients, Previously Treated With Other Basal Insulins [NCT00697450]		206 participants (Actual)	Observational	2008-07-31	Completed
A 26 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group, Treat-to-target Once Daily Treatment Trial With Insulin Detemir Versus Insulin Glargine, Both in Combination With Metformin in Subjects With Type 2 Diabetes [NCT00909480]	Phase 4	457 participants (Actual)	Interventional	2009-05-31	Completed
Trial Investigating the Hypoglycaemic Response to Single Doses of Insulin Detemir and NPH Insulin in Subjects With Type 1 Diabetes [NCT00760448]	Phase 1	25 participants (Actual)	Interventional	2004-04-30	Completed
Evaluation of Effectiveness and Safety of Levemir® (Insulin Detemir), NovoMix® (Biphasic Insulin Aspart) and/or NovoRapid® (Insulin Aspart) in Insulin naïve Subjects With Type 2 Diabetes. [NCT00771680]		10,408 participants (Actual)	Observational	2008-10-31	Completed
A Prospective, Multicentre, Non-controlled, Observational, 52-weeks Study: the Evaluation of the Body Weight Progress During the Treatment With Insulin Detemir in Type 1 or 2 Diabetes Patients, Previously Treated With Other Basal Insulins [NCT00849342]		580 participants (Actual)	Observational	2008-12-31	Completed
2 Year Efficiency and Safety Comparison of Insulin Detemir and NPH Insulin in Type 1 Diabetes. [NCT00184665]	Phase 3	501 participants (Actual)	Interventional	2004-06-30	Completed
A 20-week, Multi-centre, Open-labelled, Non-comparative Evaluation of the Safety and Efficacy of Insulin Detemir in Combination With Oral Anti-diabetic Drug(s), in Subjects With Type 2 Diabetes Mellitus Who Were Inadequately Controlled on Current Therapy [NCT00455858]	Phase 4	87 participants (Actual)	Interventional	2007-11-30	Completed
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of NN1250 at Steady State Conditions in Subjects With Type 2 Diabetes of Different Race and/or Ethnicity [NCT01043510]	Phase 1	63 participants (Actual)	Interventional	2010-01-31	Completed
A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin Versus a Twice Daily Insulin Mixture Versus a Meal-time Rapid-Acting Insulin in Subjects With Type 2 Diabetes In [NCT00184600]	Phase 3	708 participants (Actual)	Interventional	2004-11-30	Completed
INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric [NCT04974528]	Phase 3	264 participants (Anticipated)	Interventional	2021-09-29	Recruiting
The Effect of Detemir Compared to Exenatide and/or the Combination of Detemir and Exenatide on Glycemic Control and Weight in Patients With Type 2 Diabetes Mellitus Who Have Failed Oral Hypoglycemic Agents [NCT01076842]	Phase 4	75 participants (Anticipated)	Interventional	2008-04-30	Completed
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Levemir® (Insulin Detemir) in Pregnant Women With Diabetes Mellitus [NCT01892319]		2,446 participants (Actual)	Observational	2013-09-30	Completed
Transitioning Post-cardiothoracic Surgery Patients From Intravenous Insulin to the Subcutaneous Route With Insulin Detemir. [NCT00717288]	Phase 4	82 participants (Actual)	Interventional	2008-07-31	Completed
Safety of Insulin Detemir and Insulin NPH in Children With Type 1 Diabetes Mellitus [NCT00605137]	Phase 3	83 participants (Actual)	Interventional	2004-05-21	Completed
No Evidence for Essential Differences Between the Effects of Insulin Glargine, Insulin Detemir and NPH Insulin on Glucose Metabolism After a Single Injection as Assessed by 24-h Euglycemic Clamp Studies in Healthy Humans [NCT00566124]	Phase 4	10 participants (Actual)	Interventional	2005-01-31	Completed
Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart to Insulin NPH Plus Insulin Aspart in Adults With Type 1 Diabetes Mellitus [NCT00595374]	Phase 3	114 participants (Actual)	Interventional	2003-12-02	Completed
Comparison of the Efficacy and Safety of Step-wise Addition of Short Acting Insulin Analogue Insulin Aspart to Once Daily Insulin Detemir and Oral Anti-diabetic Treatment in Patients With Type 2 Diabetes [NCT00537303]	Phase 4	296 participants (Actual)	Interventional	2007-10-31	Completed
A Prospective, Multicentre, Multinational, Open Label, Non-controlled, Observational, 24-week Study in Patients Using Oral Anti-Diabetic (OAD) Drugs + Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus in Near East Region Countries [NCT00842192]		2,155 participants (Actual)	Observational	2009-04-30	Completed
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes. A 26 Week, Randomised, Open-label, Parallel-group, Multicentre, Multinational Trial With a 26 Week Extensio [NCT00856986]	Phase 3	987 participants (Actual)	Interventional	2009-03-31	Completed
Safety and Efficacy of Insulin Detemir Combined With OAD Versus Insulin NPH Combined With OAD in Type 2 Mellitus [NCT00604396]	Phase 3	477 participants (Actual)	Interventional	2003-03-31	Completed
Comparison of Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus [NCT00605020]	Phase 3	719 participants (Actual)	Interventional	2003-12-02	Completed
NN5401-3594: A 26-week, Open-labelled, Two-arm, Parallel, Randomised Trial Comparing Efficacy and Safety of NN5401 Once Daily Plus Insulin Aspart vs. Basal-bolus Treatment With Insulin Detemir Plus Insulin Aspart in Subjects With Type 1 Diabetes / NN5401- [NCT00978627]	Phase 3	548 participants (Actual)	Interventional	2009-08-31	Completed
The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial [NCT00657943]	Phase 4	415 participants (Actual)	Interventional	2008-04-30	Completed
Change in Weight on Insulin Detemir (Levemir®) or Isophane (NPH) Insulin (Insulatard®) in Patients With Type 2 Diabetes Mellitus [NCT00658099]		699 participants (Actual)	Observational	2007-11-30	Completed
Observational Study on Evaluation of Glycaemic Control in Patients Using a Modern Insulin - NovoRapid® (Insulin Aspart), NovoMix® 30 (Biphasic Insulin Aspart) or Levemir® (Insulin Detemir) - for Treatment of Diabetes Mellitus [NCT00676741]		3,809 participants (Actual)	Observational	2008-02-29	Completed
Efficacy of Metformin Treatment in Not Controlled With Diet Gestational Diabetes Versus Use of Insulin Therapy [NCT04222348]	Phase 3	200 participants (Actual)	Interventional	2016-10-26	Active, not recruiting
Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus [NCT00700765]		1,531 participants (Actual)	Observational	2008-01-31	Completed
Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs Given as a Bolus by Continuous Subcutaneous Insulin Infusion (CSII) and in MDI Basal-Bolus Therapy in Pediatric Subjects With Type 1 Diabetes (TID) [NCT00652288]	Phase 1	36 participants (Actual)	Interventional	2007-04-30	Completed
Efficacy and Safety Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening as Add-on to Oral Antidiabetic Drug(s) in Patients With Type 2 Diabetes [NCT00104182]	Phase 3	503 participants (Actual)	Interventional	2005-02-28	Completed
Efficacy of Glycaemic Control of Biphasic Insulin Aspart (NovoMix® 30) or Insulin Detemir (Levemir®) in Patients With Type 1 or 2 Diabetes Mellitus [NCT00671008]		400 participants (Actual)	Observational	2007-12-31	Completed
Comparing the Metabolic Control of Once to Twice-daily Insulin Detemir Injections in Children and Adolescence With Type 1 Diabetes Mellitus. [NCT00542399]	Phase 4	50 participants (Anticipated)	Interventional	2007-11-30	Completed
Inhaled Pre-prandial Human Insulin With the AERx® iDMS Versus s.c. Insulin Aspart in Type 2 Diabetes: A 104 Week, Open-label, Multicenter, Randomised, Trial Followed by a 12 Week Re-randomised Extension to Investigate Safety and Efficacy [NCT00331604]	Phase 3	618 participants (Actual)	Interventional	2006-08-31	Terminated(stopped due to See termination reason in detailed description)
The Effects of Insulin Detemir and Gliclazide-MR Treatments in Addition to Life-style Modification and Metformin Therapy on Endothelial Functions in Patients With Type 2 Diabetes : An Open-labelled Randomized Prospective Study [NCT01420692]		64 participants (Actual)	Interventional	2010-06-30	Completed
Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes [NCT00097084]	Phase 3	324 participants (Actual)	Interventional	2004-09-30	Completed
A Prospective, Multicentre, Open Label, Non-controlled, Observational, 26-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus in Macedonia [NCT00842894]		3,421 participants (Actual)	Observational	2009-05-31	Completed
Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH [NCT00564018]		33 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to Presumed loss of clinical equipoise between the agents being investigated)
Observational Study on Efficacy on Glycaemic Control of Slow-acting Insulin Analogue in Type 2 Diabetes [NCT00700960]		2,745 participants (Actual)	Observational	2007-06-30	Completed
The Physiological Therapy of Type 2 Diabetes - NovoRapid® FlexPen® Before Meals, Additionally Levemir® FlexPen® in the Evening or at Bedtime if Needed [NCT01487421]		2,134 participants (Actual)	Observational	2003-07-31	Completed
A Randomised, Single Centre, Double-blind, Two-period Cross-over Glucose Clamp Trial to Demonstrate Bioequivalence Between Insulin Detemir Produced by the NN729 Process and Insulin Detemir Produced by the Current Process in Healthy Subjects [NCT01490099]	Phase 1	37 participants (Actual)	Interventional	2006-08-31	Completed
The Use of a Long-Acting Sub-Cutaneous Insulin Analogue in the Management of Hyperglycaemic Emergencies [NCT00467246]		0 participants	Interventional		Withdrawn(stopped due to Ethics approval denied)
Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics [NCT02922179]		103,951 participants (Actual)	Observational	2011-01-01	Completed
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects Wit [NCT01232491]	Phase 4	611 participants (Actual)	Interventional	2010-10-29	Completed
A Multi-centre, Multinational, Open-labelled, Randomised, Parallel-Group Comparison of Insulin Detemir Plus Insulin Aspart With NPH Insulin Plus Human Soluble Insulin in Subjects With Type 1 Diabetes on a Basal-Bolus Regimen [NCT01486940]	Phase 3	598 participants (Actual)	Interventional	2002-03-31	Completed
"A Twenty-six Week, Randomized, Open-label, 2-Arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Toujeo® Compared to Standard of Care Insulin for Initiating Basal Insulin in Insulin Naïve Patients With Unco [NCT02967224]	Phase 4	705 participants (Actual)	Interventional	2015-11-05	Completed
Impact of a Self-Adjusted Titration Guideline in Subjects With Type 2 Diabetes Mellitus: A Treat-to-Target of the Efficacy and Safety of Levemir® (Insulin Detemir [rDNA Origin] Injection) (PREDICTIVE™ 303) [NCT00264901]	Phase 4	5,652 participants (Actual)	Interventional	2005-10-31	Completed
The Effect of Insulin Analogues and Human Insulin on the Incidence of Severe Hypoglycaemia in Hypoglycaemia Prone Type 1 Diabetic Patients [NCT00346996]	Phase 4	179 participants (Actual)	Interventional	2007-05-31	Completed
Comparison of Efficacy and Safety of Insulin Detemir Once or Twice Daily in a Basal-Bolus Regimen With Insulin Aspart in Patients With Type 1 Diabetes [NCT00117780]	Phase 4	520 participants (Actual)	Interventional	2005-06-30	Completed
Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake [NCT01232946]		30 participants (Actual)	Interventional	2012-01-31	Completed
Observational, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus [NCT00701155]		3,593 participants (Actual)	Observational	2007-07-31	Completed
An Observational, Safety and Efficacy Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus. [NCT00687063]		10,008 participants (Actual)	Observational	2008-04-30	Completed
Safety and Therapeutic Effect of Insulin Detemir in Taiwanese Patients With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets With OAD With/Without Once-daily NPH Insulin Treatment [NCT00521690]	Phase 4	25 participants (Actual)	Interventional	2006-12-31	Completed
Comparison of the Effect of Insulin Detemir Versus Insulin NPH Both With Insulin Aspart on Weight Change in Overweight and Obese Subjects With Type 2 Diabetes [NCT00504673]	Phase 3	277 participants (Actual)	Interventional	2005-04-30	Completed
An Assessment of the Impact of Performing Physical Exercise on the Maximum Plasma Glucose Decline in Subjects With Type 1 Diabetes Managed on a Basal Bolus Insulin Regimen: A Comparison of 3 Basal Insulin Treatments - Insulin Detemir, Insulin Glargine and [NCT00313742]	Phase 4	51 participants (Actual)	Interventional	2006-04-30	Completed
A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia [NCT01542424]		1,889 participants (Actual)	Observational	2006-03-31	Completed
A Randomised, Open-labelled, Single-centre, Two-period Crossover Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single s.c. Doses of NN304 (Insulin Detemir) and NPH Human Insulin in Japanese Subjects With Type 1 Diabetes Mellitus [NCT01542450]	Phase 1	23 participants (Actual)	Interventional	2002-08-31	Completed
Levemir®: the Physiological Basal Insulin. Documentation of Safety Aspects, Glycaemic Control and Weight [NCT01542463]		4,464 participants (Actual)	Observational	2004-09-30	Completed
An Observational Study in Dutch Type 1 and Type 2 Diabetes Patients: The Impact of Initiation of/Switching to Levemir® on Emotional Well-being, Insulin Perceptions and Treatment Satisfaction - CONFIDENCE (Clinical ObservatioNs oF Levemir® In Dutch Experie [NCT01542476]		299 participants (Actual)	Observational	2006-08-31	Completed
An Observational 3 Months Study to Evaluate the Effect of Insulin Levemir® on Glycaemic Control, Weight and Incidence of Hypoglycaemic Events in Insulin Treated Subjects With Type 1 or Type 2 Diabetes [NCT01542489]		480 participants (Actual)	Observational	2006-10-31	Completed
A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Patients Using Insulin Detemir for the Treatment of Type 1 or Type 2 Diabetes Mellitus: The PREDICTIVE™ Study - Predictable Results and Experience in Diabetes Thr [NCT01545791]		1,037 participants (Actual)	Observational	2006-05-31	Completed
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days [NCT01547169]	Phase 2	60 participants (Actual)	Interventional	2011-03-31	Completed
An Observational 3-months Study to Evaluate Efficacy and Safety of Insulin Levemir® Used as Basal Insulin on the Glycaemic Control, Weight and Incidence of Hypoglycaemic Events in Insulin Treated Subjects With Type 1 or Type 2 Diabetes [NCT01548248]		631 participants (Actual)	Observational	2006-01-31	Completed
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes [NCT00106366]	Phase 3	389 participants (Actual)	Interventional	2005-03-31	Completed
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]	Phase 3	10,251 participants (Actual)	Interventional	1999-09-30	Completed
"A Twenty-six Week, Randomized, Open-label, 2-arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Transition to Toujeo Compared to Standard of Care Insulin in Basal Insulin Treated Patients With Uncontrolled [NCT02967211]	Phase 4	609 participants (Actual)	Interventional	2015-12-21	Completed
Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir. [NCT00405418]	Phase 4	973 participants (Actual)	Interventional	2006-11-30	Completed
A Randomised Study Comparing Continuous Intravenous Insulin Infusion With Subcutaneous Insulin Analogues in Hospitalised Patients With Type II Diabetes and Hyperglycaemia [NCT00135070]	Phase 4	41 participants (Actual)	Interventional	2005-07-31	Terminated(stopped due to No documentation with MHRA to support clinical trial of a medicinal product.)
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Semilente®MC in Children, Adolescents and Young Adults With Type 1 Diabetes on Basal-Bolus Regimen. [NCT00184639]	Phase 3	71 participants (Actual)	Interventional	2004-08-16	Completed
Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes [NCT00095082]	Phase 3	447 participants (Actual)	Interventional	2004-09-30	Completed
Exploration of the Weight Neutral Effects of Insulin Detemir Compared to Insulin Glargine: A Measure of Satiety and Calories Consumed in Type 1 Diabetes [NCT00659165]		10 participants (Actual)	Interventional	2008-04-30	Completed
A 6-week, Randomised, Multi-centre, Open-labelled, Parallel Group, Exploratory Trial to Investigate the Safety of SIBA Once Daily + NovoRapid® Compared to Insulin Detemir Once Daily + NovoRapid®, All in a Basal-bolus Regimen in Subjects With Type 1 Diabet [NCT00841087]	Phase 2	65 participants (Actual)	Interventional	2009-01-31	Completed
A Crossover, Multicentre, Randomised Trial Comparing the Effect on the Control of Blood Glucose Concentration of Insulin Glargine and Insulin Detemir, Combined With Insulin Glulisine, Used as a Bolus, in Type 1 Diabetic Patients [NCT00271284]	Phase 3	88 participants (Actual)	Interventional	2005-10-31	Completed
Efficacy and Safety of Insulin Aspart in a Fixed or Flexible Supplementary Insulin Therapy Regimen, With or Without Insulin Detemir in Type 2 Diabetes [NCT00274274]	Phase 4	373 participants (Actual)	Interventional	2005-09-30	Completed
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine as Add-on to Current Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes [NCT00283751]	Phase 3	583 participants (Actual)	Interventional	2003-03-31	Completed
Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes [NCT00312156]	Phase 3	347 participants (Actual)	Interventional	2002-08-31	Completed
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes. [NCT00312104]	Phase 3	325 participants (Actual)	Interventional	2002-04-30	Completed
A Single-centre, Parallel-group, Randomised, Double Blind Trial in Healthy Japanese Subjects Comparing the Within-subject Variability of Insulin Detemir and Insulin Glargine With Respect to Pharmacodynamic and Pharmacokinetic Properties [NCT01497535]	Phase 1	40 participants (Actual)	Interventional	2004-05-27	Completed
A Randomised, Double-blind, Four-period, Cross-over, Dose Response Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single Doses of Insulin Detemir and NPH Insulin in Subjects With Type 2 Diabetes [NCT01497561]	Phase 1	15 participants (Actual)	Interventional	2003-03-31	Completed
A Single-centre, Randomised, Double-blind, Cross-over Trial Comparing the Within-subject Variability of the Pharmacokinetic Profiles of Insulin Detemir and Insulin Glargine in Children and Adolescents With Type 1 Diabetes [NCT01497574]	Phase 1	32 participants (Actual)	Interventional	2005-05-31	Completed
A Single Centre, Open-labelled Trial to Investigate the Pharmacokinetics of Insulin Detemir in Healthy Taiwanese Subjects [NCT01497587]	Phase 1	20 participants (Actual)	Interventional	2005-08-31	Completed
A Randomised, Double-blind, Six-period, Cross-over, Dose-response Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single Doses of Insulin Detemir and NPH Insulin in Subjects of Blacks or African American, Whites of Hispanic or Latino Orig [NCT01497600]	Phase 1	50 participants (Actual)	Interventional	2004-02-29	Completed
A Randomised, Single Centre, Two-period, Cross-over, Glucose Clamp Trial to Test for Bioequivalence Between Two Insulin Detemir Formulations Containing Mannitol and Glycerol as Isotonic Agents Respectively, in Healthy Subjects [NCT01498926]	Phase 1	34 participants (Actual)	Interventional	2005-11-30	Completed
A Single Centre, Randomised, Double-blind, Three-period Cross-over Trial to Investigate the 24-hour Pharmacokinetics After Single Dose of Insulin Detemir in Healthy Chinese Male Subjects [NCT01498939]	Phase 1	20 participants (Actual)	Interventional	2007-08-31	Completed
A Randomised, Open Label, Cross-over, Multi-centre, Multinational Trial Comparing the Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir and NPH Insulin in Well Controlled Subjects With Type 1 Diabetes on a Basal-bolus Regimen [NCT01697657]	Phase 3	131 participants (Actual)	Interventional	2001-09-30	Completed
A Multicentre, Open Label, Nonrandomised, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus [NCT01709929]	Phase 3	2,287 participants (Actual)	Interventional	2005-10-31	Completed
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabet [NCT01835431]	Phase 3	362 participants (Actual)	Interventional	2013-10-17	Completed
Impact of Insulin Detemir Versus Insulin Glargine on Glycaemic Control and Metabolism During Exercise in Type 1 Diabetes [NCT01440439]	Phase 4	30 participants (Anticipated)	Interventional	2011-11-30	Recruiting
Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on IGFBP-1 Production and Serum IGF-I in Subjects With Type 1 Diabetes Mellitus: An Open-label, Randomised, Triple Cross-over Trial [NCT01461616]	Phase 3	19 participants (Actual)	Interventional	2012-02-29	Completed
New Onset Type 1 Diabetes: Role of Exenatide [NCT01269034]	Phase 4	13 participants (Actual)	Interventional	2010-12-31	Completed
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120) [NCT01595646]	Phase 2	37 participants (Actual)	Interventional	2011-11-30	Completed
A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes [NCT05134987]	Phase 1	30 participants (Actual)	Interventional	2021-12-01	Completed
The Relative Effectiveness of Pumps Over Multiple Dose Injections and Structured Education Trial [NCT01616784]	Phase 3	267 participants (Actual)	Interventional	2011-11-30	Completed
Effect of Two Different Fasting Blood Glucose Titration Targets in Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily in Combination With 1-3 Oral Agents [NCT00634842]	Phase 4	244 participants (Actual)	Interventional	2008-02-29	Completed
The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients [NCT02496780]	Phase 2/Phase 3	66 participants (Actual)	Interventional	2015-08-31	Completed
A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on G [NCT02131272]	Phase 3	42 participants (Actual)	Interventional	2014-06-11	Terminated
A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in Insulin-naive Patients With Uncontrolled Type 2 Diabete [NCT02451137]	Phase 4	3,304 participants (Actual)	Interventional	2015-06-16	Completed
Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes [NCT00383877]	Phase 3	263 participants (Actual)	Interventional	2006-09-30	Completed
Prevention of Stress Hyperglycemia With the Use of DPP-4 Inhibitors in Non-diabetic Patients Undergoing Non-cardiac Surgery, a Pilot Study [NCT02741687]	Phase 4	80 participants (Actual)	Interventional	2016-06-30	Completed
The Effect of Insulin Detemir on Glucose Control in Ageing Subjects With Type 2 Diabetes. [NCT00506662]	Phase 4	86 participants (Actual)	Interventional	2007-07-31	Terminated(stopped due to See termination reason in detailed description)
Management of Hyperglycemia in the Emergency Room: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care [NCT00591227]	Phase 4	176 participants (Actual)	Interventional	2008-05-31	Completed
A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus: The PREDICTIVE™ Study: Predictable Results and Experienc [NCT00659295]		51,170 participants (Actual)	Observational	2004-06-30	Completed
A 26-week, Multinational, Multi-centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Degludec and Insulin Detemir in Children and Adolescents 1 to Less Than 18 Years With Type 1 Diabetes Mellitus on a Basal-bolus Regimen [NCT01513473]	Phase 3	350 participants (Actual)	Interventional	2012-01-16	Completed
A Randomised, Multicentric, Open Labelled, Parallel Group Trial With Insulin Aspart and Insulin Detemir, Investigating the Glycaemic Effect and Profile in Children With Type 1 Diabetes, of Two Separate Levemir® + NovoRapid® Injections and Extemporaneous M [NCT00542620]	Phase 4	25 participants (Actual)	Interventional	2007-09-30	Completed
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes [NCT01831765]	Phase 3	1,290 participants (Actual)	Interventional	2013-08-26	Completed
The Effect of Simple Insulin Detemir Titration, Metformin Plus Liraglutide Compared to Simple Insulin Detemir Titration Plus Insulin Aspart and Metformin for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study: A 26 Week, Randomized, Open Label, P [NCT01966978]	Phase 4	157 participants (Actual)	Interventional	2014-11-30	Completed
Effectiveness of a Subcutaneously Administered Long-Acting Insulin Detemir Added to Insulin Drip Therapy as Compared With Standard Insulin Drip Treatment [NCT01186003]		30 participants (Actual)	Interventional	2010-08-31	Completed
A 2-week, Randomised, Controlled, Open-label, Two-group Parallel, Multi-centre Trial Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin Both in a Basal Bolus Regimen With or Without Metformin in [NCT01486966]	Phase 4	58 participants (Actual)	Interventional	2011-11-30	Terminated(stopped due to Trial terminated prematurely due to slow recruitment.)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monothe [NCT02033889]	Phase 3	621 participants (Actual)	Interventional	2013-12-13	Completed
A 20-week, Randomised, Multi-centre, Open-labelled Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Titration Algorithms (3-0-3 Algorithm and 2-4-6-8 Algorithm) After 20 Weeks in Subjects With Type 2 Diabetes Mell [NCT01868542]	Phase 4	46 participants (Actual)	Interventional	2013-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00000620 (6) [back to overview]	Stroke in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]	Death From Any Cause in the Glycemia Trial.
NCT00184600 (15) [back to overview]	Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 12 Months
NCT00184600 (15) [back to overview]	Percentage of Participants (Total Participants and the Subset of Participants Who Did Not Have an Hypoglycaemic Episode) Achieving a Month 12 Value in HbA1c Below or Equal to 6.5%
NCT00184600 (15) [back to overview]	Number of Hypoglycaemic Events Per Participant Per Year at Month 36 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%
NCT00184600 (15) [back to overview]	HbA1c (Glycosylated Haemoglobin) at Month 12
NCT00184600 (15) [back to overview]	Number of Hypoglycaemic Events Per Participant Per Year at Month 12 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%
NCT00184600 (15) [back to overview]	HbA1c (Glycosylated Haemoglobin) at Month 36
NCT00184600 (15) [back to overview]	Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 36 Months
NCT00184600 (15) [back to overview]	Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 36 Months
NCT00184600 (15) [back to overview]	Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 12 Months
NCT00184600 (15) [back to overview]	Percentage of Participants Who Required A Second Insulin Therapy by Month 36
NCT00184600 (15) [back to overview]	Percentage of Participants Who Required A Second Insulin Therapy by Month 12
NCT00184600 (15) [back to overview]	Percentage of Participants Achieving a Month 36 Value in HbA1c Below or Equal to 6.5%
NCT00184600 (15) [back to overview]	Number of Participants Having an 'Other' Adverse Event
NCT00184600 (15) [back to overview]	Change From Baseline in Body Weight at Month 36
NCT00184600 (15) [back to overview]	Change From Baseline in Body Weight at Month 12
NCT00435019 (3) [back to overview]	Observed Insulin Antibody Values
NCT00435019 (3) [back to overview]	Number of Subjects Reporting Adverse Events
NCT00435019 (3) [back to overview]	Glycosylated Haemoglobin A1c (HbA1c)
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Haematology - Leucocytes)
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Haematology - Lymphocytes)
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Haematology - Monocytes)
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Haematology - Thrombocytes)
NCT00447382 (24) [back to overview]	Glycaemic Control Parameters (9-point Self Measured Plasma Glucose [SMPG])
NCT00447382 (24) [back to overview]	Glycaemic Control Parameters (Change in Fasting Plasma Glucose [FPG])
NCT00447382 (24) [back to overview]	Glycaemic Control Parameters (Change in HbA1c)
NCT00447382 (24) [back to overview]	Hypoglycaemic Episodes
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Haematology - Neutrophils)
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Biochemistry - Sodium)
NCT00447382 (24) [back to overview]	Adverse Events
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Biochemistry - Alanine Aminotransferase [ALAT])
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Biochemistry - Albumin)
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Biochemistry - Alkaline Phosphatase [ALP])
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Biochemistry - Creatinine)
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Biochemistry - Lactate Dehydrogenase [LDH])
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Biochemistry - Potassium)
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Biochemistry - Total Protein)
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Haematology - Basophilis)
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Haematology - Eosinophils)
NCT00447382 (24) [back to overview]	Clinical Laboratory Values (Change in Haematology - Haemoglobin)
NCT00447382 (24) [back to overview]	Change From Baseline in Total Antibodies
NCT00447382 (24) [back to overview]	Change From Baseline in Detemir Specific Antibodies
NCT00447382 (24) [back to overview]	Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies
NCT00455858 (5) [back to overview]	Percentage of Subjects Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than 7.0%
NCT00455858 (5) [back to overview]	Occurence of Hypoglycaemic Episodes
NCT00455858 (5) [back to overview]	Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 20
NCT00455858 (5) [back to overview]	Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 12
NCT00455858 (5) [back to overview]	Change in Fasting Plasma Glucose (FPG)
NCT00467649 (12) [back to overview]	Change in Body Weight From Baseline at Week 24
NCT00467649 (12) [back to overview]	Phase 2: Change in HbA1c at Week 36
NCT00467649 (12) [back to overview]	Phase 2: Change in Body Weight at Week 36
NCT00467649 (12) [back to overview]	Hypoglycemia Adverse Events
NCT00467649 (12) [back to overview]	Fasting Serum Lipids Change From Baseline to Week 24
NCT00467649 (12) [back to overview]	The Percentage of Patients Achieving HbA1c <=7% at Week 24 With no Gain in Body Weight From Baseline and no Incidence of Severe Hypoglycemia
NCT00467649 (12) [back to overview]	Percentage of Patients With a Severe Hypoglycemia Adverse Event
NCT00467649 (12) [back to overview]	Percentage of Patients Achieving HbA1c <=7% at Week 24
NCT00467649 (12) [back to overview]	Change in Waist Circumference From Baseline at Week 24
NCT00467649 (12) [back to overview]	Change in HbA1c From Baseline at Week 24
NCT00467649 (12) [back to overview]	Change in Fasting Plasma Glucose From Baseline at Week 24
NCT00467649 (12) [back to overview]	Percentage of Patients With no Weight Gain at Week 24
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Haemoglobin Level (Haematology)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Insulin Aspart Specific Antibodies
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Insulin Detemir Specific Antibodies
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Insulin Detemir/Insulin Aspart Cross Reacting Antibodies
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Lactate Dehydrogenase Serum Level (Biochemistry)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Leukocytes Level (Haematology)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Potassium Serum Level (Biochemistry)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Sodium Serum Level (Biochemistry)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Thrombocytes Level (Haematology)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Total Protein Serum Level (Biochemistry)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Urine Albumin Level (Urinalysis)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Urine N (Creatinine) (Urinalysis)
NCT00474045 (47) [back to overview]	Maternal Safety - Hypoglycaemic Episodes
NCT00474045 (47) [back to overview]	Maternal Safety - Mode of Delivery
NCT00474045 (47) [back to overview]	Maternal Safety - Number of Subjects With Adverse Events (AEs)
NCT00474045 (47) [back to overview]	Pregnancy Outcome at Delivery
NCT00474045 (47) [back to overview]	Pregnancy Outcome at Follow-Up
NCT00474045 (47) [back to overview]	Safety - Composite Pregnancy Outcome
NCT00474045 (47) [back to overview]	Safety - Total Daily Insulin Dose During Pregnancy
NCT00474045 (47) [back to overview]	Safety in Children - Number of Subjects (Foetuses and Newborns) With Adverse Events
NCT00474045 (47) [back to overview]	Glycosylated Haemoglobin (HbA1c) for Full Analysis Set (Pregnant Subjects) at GW 36
NCT00474045 (47) [back to overview]	Glycosylated Haemoglobin (HbA1c) for Per Protocol Analysis Set (Pregnant Subjects) at GW 36
NCT00474045 (47) [back to overview]	Maternal Safety - Acceleration of Nephropathy
NCT00474045 (47) [back to overview]	Maternal Safety - Electrocardiogram (ECG)
NCT00474045 (47) [back to overview]	Maternal Safety - Nocturnal Hypoglycaemic Episodes
NCT00474045 (47) [back to overview]	Pregnancy Outcome Safety - Level of Aspart Specific Antibodies (AB) in Umbilical Cord Blood
NCT00474045 (47) [back to overview]	Pregnancy Outcome Safety - Level of Cross-Reacting Antibodies (AB) in Umbilical Cord Blood
NCT00474045 (47) [back to overview]	8-point Self Monitored Plasma Glucose (SMPG) Profile at GW 36
NCT00474045 (47) [back to overview]	Pregnancy Outcome Safety - Level of Detemir Specific Antibodies (AB) in Umbilical Cord Blood
NCT00474045 (47) [back to overview]	Pregnancy Outcome Safety - Level of Insulin Detemir in Umbilical Cord Blood
NCT00474045 (47) [back to overview]	Ratio Between Aspart Specific Antibodies in Cord Blood and Maternal Antibodies
NCT00474045 (47) [back to overview]	Ratio Between Cross-reacting Antibodies in Cord Blood and Maternal Antibodies
NCT00474045 (47) [back to overview]	Ratio Between Detemir Specific Antibodies in Cord Blood and Maternal Antibodies
NCT00474045 (47) [back to overview]	Subjects Reaching HbA1c at or Below 6.0% Both at GW 24 and GW 36
NCT00474045 (47) [back to overview]	8-point Self-monitored Plasma Glucose (SMPG) Profile at GW 24
NCT00474045 (47) [back to overview]	Fasting Plasma Glucose (FPG)
NCT00474045 (47) [back to overview]	Glycosylated Haemoglobin (HbA1c) During Pregnancy
NCT00474045 (47) [back to overview]	Maternal Safety - Acceleration of Retinopathy in Any Eye
NCT00474045 (47) [back to overview]	Maternal Safety - Change From Visit P1 in Body Weight During Pregnancy by Visit
NCT00474045 (47) [back to overview]	Maternal Safety - Change From Visit P1 in Diastolic Blood Pressure During Pregnancy and at Follow-Up by Visit
NCT00474045 (47) [back to overview]	Maternal Safety - Change From Visit P1 in Pulse During Pregnancy and at Follow-Up
NCT00474045 (47) [back to overview]	Maternal Safety - Change From Visit P1 in Systolic Blood Pressure During Pregnancy and at Follow-Up by Visit
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Alanine Aminotransferase Serum Level (Biochemistry)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Albumin Serum Level (Biochemistry)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Albumin/Creatinine Ratio (Urinalysis)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Alkaline Phosphatase Serum Level (Biochemistry)
NCT00474045 (47) [back to overview]	Maternal Safety - Change in Creatinine Serum Level (Biochemistry)
NCT00487240 (11) [back to overview]	30-Day Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including Nocturnal, Non-Nocturnal, and Severe) Overall and at Endpoint
NCT00487240 (11) [back to overview]	Number of Self-Reported Hypoglycemic Episodes (Including Nocturnal, Non-Nocturnal, and Severe Hypoglycemia) Overall and at Endpoint
NCT00487240 (11) [back to overview]	Percentage of Patients With Hemoglobin A1c (HbA1c) Less Than or Equal to 7.0% and HbA1c Less Than or Equal to 6.5%
NCT00487240 (11) [back to overview]	1-Year Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including Nocturnal, Non-Nocturnal, and Severe) Overall and at Endpoint
NCT00487240 (11) [back to overview]	7-Point Self-Monitored Blood Glucose (SMBG) at Endpoint
NCT00487240 (11) [back to overview]	Actual and Change From Baseline Hemoglobin A1c (HbA1c) Values
NCT00487240 (11) [back to overview]	Change From Baseline in Absolute Body Weight at 32 Week Endpoint
NCT00487240 (11) [back to overview]	Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint
NCT00487240 (11) [back to overview]	Glycemic Variability at Endpoint
NCT00487240 (11) [back to overview]	Insulin Dose (Total and By Component [Basal and Bolus])
NCT00487240 (11) [back to overview]	Insulin Dose Per Body Weight (Total and By Component [Basal and Bolus])
NCT00506662 (3) [back to overview]	Mean Number of Total Hypoglycaemic Episodes, Month 1
NCT00506662 (3) [back to overview]	Mean Number of Total Hypoglycaemic Episodes, Months 5-7
NCT00506662 (3) [back to overview]	Mean Number of Total Hypoglycaemic Episodes, Months 2-4
NCT00509925 (18) [back to overview]	Component of Total Energy Expenditure: Physical Activity Thermogenesis
NCT00509925 (18) [back to overview]	Component of Total Energy Expenditure: Resting Energy Expenditure (REE)
NCT00509925 (18) [back to overview]	Hypoglycaemic Episodes
NCT00509925 (18) [back to overview]	Total Energy Expenditure, Dietary Record Method
NCT00509925 (18) [back to overview]	Total Energy Expenditure, Double-labelled Water Method
NCT00509925 (18) [back to overview]	Lean Body Mass
NCT00509925 (18) [back to overview]	Hypoglycaemic Episodes, Diurnal/Nocturnal
NCT00509925 (18) [back to overview]	Hormonal Assessment: Resistin
NCT00509925 (18) [back to overview]	Component of Total Energy Expenditure: Diet Induced Thermogenesis (DIT)
NCT00509925 (18) [back to overview]	Hormonal Assessment: Leptin
NCT00509925 (18) [back to overview]	Hormonal Assessment: Insulin-like Growth Factor-1
NCT00509925 (18) [back to overview]	Hormonal Assessment: Adiponectin
NCT00509925 (18) [back to overview]	Glycosylated Haemoglobin A1c (HbA1c)
NCT00509925 (18) [back to overview]	Fat Mass
NCT00509925 (18) [back to overview]	Fasting Plasma Glucose
NCT00509925 (18) [back to overview]	Body Weight
NCT00509925 (18) [back to overview]	Component of Total Energy Expenditure: Non-exercise Activity Thermogenesis (NEAT)
NCT00509925 (18) [back to overview]	Waist:Hip Ratio
NCT00537303 (6) [back to overview]	Cardiovascular Risk Marker: High-sensitivity C-reactive Peptide
NCT00537303 (6) [back to overview]	Biochemistry: Serum Alanine Aminotransferase
NCT00537303 (6) [back to overview]	Hypoglycaemic Episodes
NCT00537303 (6) [back to overview]	Glycosylated Haemoglobin A1c (HbA1c)
NCT00537303 (6) [back to overview]	Glycosylated Haemoglobin A1c (HbA1c)
NCT00537303 (6) [back to overview]	Haematology: Haemoglobin Measured in Blood
NCT00542620 (30) [back to overview]	Incidence of Hypoglycaemic Episodes - All Episodes
NCT00542620 (30) [back to overview]	Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to the Time of the Last Measured Level of Insulin Aspart
NCT00542620 (30) [back to overview]	Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to the Time of the Last Measured Level of Insulin Detemir
NCT00542620 (30) [back to overview]	Pharmacokinetics: Cmax of Free Insulin
NCT00542620 (30) [back to overview]	Pharmacokinetics: Cmax of Insulin Aspart
NCT00542620 (30) [back to overview]	Pharmacokinetics: Cmax of Insulin Detemir
NCT00542620 (30) [back to overview]	Pharmacokinetics: Terminal Phase Elimination Half-life (T½) - Parameter of Free Insulin
NCT00542620 (30) [back to overview]	Pharmacokinetics: Terminal Phase Elimination Half-life (T½) - Parameter of Insulin Aspart
NCT00542620 (30) [back to overview]	Pharmacokinetics: Terminal Phase Elimination Half-life (T½) - Parameter of Insulin Detemir
NCT00542620 (30) [back to overview]	Pharmacokinetics: Tmax of Free Insulin
NCT00542620 (30) [back to overview]	Pharmacokinetics: Tmax of Insulin Aspart
NCT00542620 (30) [back to overview]	Pharmacokinetics: Tmax of Insulin Detemir
NCT00542620 (30) [back to overview]	Weight Z Score
NCT00542620 (30) [back to overview]	Self-measured Plasma Glucose Profile (After Breakfast)
NCT00542620 (30) [back to overview]	Self-measured Plasma Glucose Profile (After Dinner)
NCT00542620 (30) [back to overview]	Self-measured Plasma Glucose Profile (Before Breakfast)
NCT00542620 (30) [back to overview]	Self-measured Plasma Glucose Profile (Before Dinner)
NCT00542620 (30) [back to overview]	Incidence of Hypoglycaemic Episodes - Glycaemia Above or Equal to 0.56 g/L
NCT00542620 (30) [back to overview]	"Percentage of Children Assessing Insulin Therapy Injection Pain as Happy Face"
NCT00542620 (30) [back to overview]	"Percentage of Children Assessing Insulin Therapy Injection Pain as Sad Face"
NCT00542620 (30) [back to overview]	"Percentage of Children Assessing Insulin Therapy Injection Pain as Very Happy Face"
NCT00542620 (30) [back to overview]	Body Mass Index (BMI) Z Score
NCT00542620 (30) [back to overview]	Fructosamine
NCT00542620 (30) [back to overview]	Glycosylated Haemoglobin A1c (HbA1c)
NCT00542620 (30) [back to overview]	Glycosylated Haemoglobin A1c (HbA1c)
NCT00542620 (30) [back to overview]	Incidence of Hypoglycaemic Episodes - Glycaemia Below 0.56 g/L
NCT00542620 (30) [back to overview]	Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to Infinity of Free Insulin
NCT00542620 (30) [back to overview]	Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to Infinity of Insulin Aspart
NCT00542620 (30) [back to overview]	Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to Infinity of Insulin Detemir
NCT00542620 (30) [back to overview]	Pharmacokinetics: Area Under the Concentration vs. Time Curve From Time Zero to the Time of the Last Measured Level of Free Insulin
NCT00564018 (2) [back to overview]	C-peptide Area Under the Curve
NCT00564018 (2) [back to overview]	Glycemic Control as Determined by HgbA1c Values at 6 Months After Diagnosis
NCT00564395 (1) [back to overview]	Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Either Insulin Detemir Mixed With Rapid Acting Insulin (RAI) or Insulin Detemir and RAI as Separate Subcutaneous Injections
NCT00591227 (1) [back to overview]	Hospital Length of Stay
NCT00623194 (17) [back to overview]	Laboratory Values: Sodium Serum, Potassium Serum and Haemoglobin (mmol/L)
NCT00623194 (17) [back to overview]	Diabetic Ketoacidosis
NCT00623194 (17) [back to overview]	Laboratory Values: Leukocytes and Thrombocytes
NCT00623194 (17) [back to overview]	Fundoscopy/Fundus Photography
NCT00623194 (17) [back to overview]	Insulin Dose
NCT00623194 (17) [back to overview]	BMI (Body Mass Index)
NCT00623194 (17) [back to overview]	Laboratory Values: Alkaline Phosphatase Serum, Alanine Aminotransferase Serum and Lactate Dehydrogenase Serum (U/L)
NCT00623194 (17) [back to overview]	Laboratory Values: Albumin Serum and Total Protein Serum (g/dL)
NCT00623194 (17) [back to overview]	Hypoglycaemic Episodes
NCT00623194 (17) [back to overview]	Insulin Detemir-insulin Aspart Cross-reacting Antibodies
NCT00623194 (17) [back to overview]	Laboratory Values: Creatine Serum Umol/L
NCT00623194 (17) [back to overview]	SD-score (Z-score) for Body Weight
NCT00623194 (17) [back to overview]	Vital Signs: Pulse
NCT00623194 (17) [back to overview]	Development of Insulin Detemir Specific Antibodies and Insulin Aspart Specific Antibodies
NCT00623194 (17) [back to overview]	Vital Signs: Blood Pressure
NCT00623194 (17) [back to overview]	Glycosylated Haemoglobin A1c (HbA1c)
NCT00623194 (17) [back to overview]	Fasting Plasma Glucose Values
NCT00634842 (4) [back to overview]	Percentage of Participants Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than 7%
NCT00634842 (4) [back to overview]	Change in Glycosylated Haemoglobin A1c (HbA1c) Percentage From Baseline
NCT00634842 (4) [back to overview]	Percentage of Participants Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than or Equal to 6.5%
NCT00634842 (4) [back to overview]	Incidence of Hypoglycaemic Episodes (All, Major, Minor and Symptoms Only)
NCT00659165 (1) [back to overview]	Calories Consumed After Fast.
NCT00659295 (1) [back to overview]	Incidence of Serious Adverse Reactions, Including Major Hypoglycaemic Events
NCT00717288 (3) [back to overview]	Patients With Hypoglycemia (Defined as Glucose <65 mg/dl)
NCT00717288 (3) [back to overview]	Patients With Morning (AM) Glucose Between 80-130 mg/dl on Day 2 and 3
NCT00717288 (3) [back to overview]	Reversion to Intravenous Insulin for Failure of Glycemic Control
NCT00789191 (12) [back to overview]	Change in BMI (Body Mass Index)
NCT00789191 (12) [back to overview]	Change in Body Weight
NCT00789191 (12) [back to overview]	HbA1c (Glycosylated Haemoglobin A1c)
NCT00789191 (12) [back to overview]	Hypoglycemic Episodes
NCT00789191 (12) [back to overview]	Hypoglycemic Episodes: Day Time
NCT00789191 (12) [back to overview]	Hypoglycemic Episodes: Night Time
NCT00789191 (12) [back to overview]	Number of Subjects Achieving HbA1c Less Than or Equal to 6.5%
NCT00789191 (12) [back to overview]	Number of Subjects Achieving HbA1c Less Than or Equal to 6.5% Without Symptomatic Hypoglycaemia
NCT00789191 (12) [back to overview]	Number of Subjects Achieving HbA1c Less Than or Equal to 7.0%
NCT00789191 (12) [back to overview]	Number of Subjects Achieving HbA1c Less Than or Equal to 7.0% Without Symptomatic Hypoglycaemia
NCT00789191 (12) [back to overview]	Self-measured 9-point Plasma Glucose Profile
NCT00789191 (12) [back to overview]	FPG (Fasting Plasma Glucose)
NCT00795600 (56) [back to overview]	Absolute Change in Fasting Plasma Glucose (FPG)
NCT00795600 (56) [back to overview]	Absolute Change in Adiponectin
NCT00795600 (56) [back to overview]	Absolute Change in Alanine Aminotransferase (ALAT)
NCT00795600 (56) [back to overview]	Absolute Change in Albumin
NCT00795600 (56) [back to overview]	Absolute Change in Alkaline Phosphatase
NCT00795600 (56) [back to overview]	Absolute Change in Aspartate Aminotransferase (ASAT)
NCT00795600 (56) [back to overview]	Absolute Change in Basophils
NCT00795600 (56) [back to overview]	Absolute Change in Urea
NCT00795600 (56) [back to overview]	Absolute Change in Blood Volume (Haematocrit)
NCT00795600 (56) [back to overview]	Percentage Change in Visceral Adipose Tissue Area
NCT00795600 (56) [back to overview]	Percentage Change in Trunk Lean Mass
NCT00795600 (56) [back to overview]	Percentage Change in Trunk Fat Mass (Defined as Peripheral Fat Ratio)
NCT00795600 (56) [back to overview]	Percentage Change in Subcutaneous Adipose Tissue Area
NCT00795600 (56) [back to overview]	Absolute Change in Calculated Trunk Fat Percentage
NCT00795600 (56) [back to overview]	Absolute Change in Calculated Visceral/Subcutaneous Adipose Tissue Ratio
NCT00795600 (56) [back to overview]	Absolute Change in Calculated Whole Body Fat Percentage
NCT00795600 (56) [back to overview]	Absolute Change in Creatine Phosphokinase
NCT00795600 (56) [back to overview]	Percentage Change in Liver/Spleen Attenuation Ratio
NCT00795600 (56) [back to overview]	Absolute Change in Visceral Adipose Tissue Area
NCT00795600 (56) [back to overview]	Absolute Change in Bilirubin Total
NCT00795600 (56) [back to overview]	Percentage Change in Calculated Visceral/Subcutaneous Adipose Tissue Ratio
NCT00795600 (56) [back to overview]	Number of Non-serious Adverse Events
NCT00795600 (56) [back to overview]	Number of Hypoglycaemic Episodes
NCT00795600 (56) [back to overview]	Absolute Change in Creatinine
NCT00795600 (56) [back to overview]	Absolute Change in Eosinophils
NCT00795600 (56) [back to overview]	Absolute Change in Erythrocytes
NCT00795600 (56) [back to overview]	Absolute Change in Whole Body Lean Mass
NCT00795600 (56) [back to overview]	Absolute Change in Whole Body Fat Mass
NCT00795600 (56) [back to overview]	Absolute Change in Waist Circumference
NCT00795600 (56) [back to overview]	Absolute Change in Very Low Density Lipoprotein (VLDL) Cholesterol
NCT00795600 (56) [back to overview]	Absolute Change in Trunk Lean Mass
NCT00795600 (56) [back to overview]	Absolute Change in Trunk Fat Mass
NCT00795600 (56) [back to overview]	Absolute Change in Triglycerides
NCT00795600 (56) [back to overview]	Absolute Change in Total Cholesterol
NCT00795600 (56) [back to overview]	Absolute Change in Body Weight
NCT00795600 (56) [back to overview]	Absolute Change in Thrombocytes
NCT00795600 (56) [back to overview]	Absolute Change in Subcutaneous Adipose Tissue Area
NCT00795600 (56) [back to overview]	Absolute Change in Sodium
NCT00795600 (56) [back to overview]	Absolute Change in Potassium
NCT00795600 (56) [back to overview]	Absolute Change in PAI-1 (Plasminogen Activator Inhibitor-1)
NCT00795600 (56) [back to overview]	Absolute Change in Neutrophils
NCT00795600 (56) [back to overview]	Absolute Change in Monocytes
NCT00795600 (56) [back to overview]	Absolute Change in Lymphocytes
NCT00795600 (56) [back to overview]	Percentual Change in Calculated Whole Body Fat Percentage
NCT00795600 (56) [back to overview]	Absolute Change in Low Density Lipoprotein (LDL) Cholesterol
NCT00795600 (56) [back to overview]	Absolute Change in Liver/Spleen Attenuation Ratio
NCT00795600 (56) [back to overview]	Absolute Change in Leucocytes
NCT00795600 (56) [back to overview]	Absolute Change in hsCRP (Highly Sensitive C Reactive Protein)
NCT00795600 (56) [back to overview]	Absolute Change in Hip Circumference
NCT00795600 (56) [back to overview]	Percentage Change in Whole Body Fat Mass
NCT00795600 (56) [back to overview]	Percentage Change in Whole Body Lean Mass
NCT00795600 (56) [back to overview]	Percentual Change in Calculated Trunk Fat Percentage
NCT00795600 (56) [back to overview]	Absolute Change in High Density Lipoprotein (HDL) Cholesterol
NCT00795600 (56) [back to overview]	Absolute Change in HbA1c (Glycosylated Haemoglobin)
NCT00795600 (56) [back to overview]	Absolute Change in Haemoglobin
NCT00795600 (56) [back to overview]	Absolute Change in Free Fatty Acids
NCT00841087 (7) [back to overview]	Diastolic Blood Pressure (BP)
NCT00841087 (7) [back to overview]	Number of Treatment Emergent Adverse Events (AEs)
NCT00841087 (7) [back to overview]	Rate of Major and Minor Hypoglycaemic Episodes
NCT00841087 (7) [back to overview]	Rate of Nocturnal Major and Minor Hypoglycaemic Episodes
NCT00841087 (7) [back to overview]	Systolic Blood Pressure (BP)
NCT00841087 (7) [back to overview]	Change in Body Weight
NCT00841087 (7) [back to overview]	Electrocardiogram (ECG)
NCT00856986 (30) [back to overview]	Mean Changes From Randomisation in Cholesterol Lipids at Week 52.
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Waist Circumference at Week 26.
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Lipids: Free Fatty Acids (FFA) at Week 52
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Lipids: Free Fatty Acids (FFA) at Week 26
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Hip Circumference at Week 52
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Hip Circumference at Week 26
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Lipids: Triglycerides at Week 26
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (Values Before Intensification as LOCF)
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Waist to Hip Ratio at Week 26
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (for Intensified Subjects in Original Treatment Group)
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Fasting Pro-insulin at Week 52
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Fasting Pro-insulin at Week 26.
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Body Weight at Week 52
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Fasting Plasma Glucose at Week 52
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Fasting Plasma Glucose at Week 26
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Fasting C-peptide at Week 52.
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.
NCT00856986 (30) [back to overview]	Hypoglycaemic Episodes Weeks 0-52
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Fasting C-peptide at Week 26.
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Body Weight at Week 26
NCT00856986 (30) [back to overview]	Adverse Events From Run-in (Week -12) to Week 52
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Lipids: Triglycerides at Week 52
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Waist Circumference at Week 52.
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Waist to Hip Ratio at Week 52
NCT00856986 (30) [back to overview]	Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-26
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in 7-point Plasma Glucose Profile (Self-measured) at Week 26
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in 7-point Plasma Glucose Profile (Self-measured) at Week 52
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Blood Pressure (Systolic and Diastolic) at Week 26.
NCT00856986 (30) [back to overview]	Mean Change From Randomisation in Blood Pressure (Systolic and Diastolic) at Week 52.
NCT00856986 (30) [back to overview]	Mean Changes From Randomisation in Cholesterol Lipids at Week 26.
NCT00909480 (14) [back to overview]	Hypoglycemic Episodes, Unclassifiable
NCT00909480 (14) [back to overview]	Incidence of Hypoglycaemic Episodes During the Trial
NCT00909480 (14) [back to overview]	Glycaemic Control as Measured by Plasma Glucose (9-point Self-measured Profiles)
NCT00909480 (14) [back to overview]	Percentage of Subjects Achieving HbA1c Less Than or Equal to 7.0%
NCT00909480 (14) [back to overview]	Percentage of Subjects Achieving HbA1c of 7% or Less With no Hypoglycaemia
NCT00909480 (14) [back to overview]	Within-subject Variation of Self Measured Plasma Glucose (SMPG) Before Breakfast
NCT00909480 (14) [back to overview]	Percentage of Subjects Achieving HbA1c Less Than or Equal to 6.5%
NCT00909480 (14) [back to overview]	Percentage of Subjects Achieving HbA1c of 6.5% or Less With no Hypoglycaemia
NCT00909480 (14) [back to overview]	"Number of Subjects Having the Adverse Event Incorrect Dose Administered"
NCT00909480 (14) [back to overview]	Change in Body Weight From Baseline
NCT00909480 (14) [back to overview]	Change in HbA1c From Baseline
NCT00909480 (14) [back to overview]	Fasting Plasma Glucose (FPG)
NCT00909480 (14) [back to overview]	Hypoglycaemic Episodes, Diurnal
NCT00909480 (14) [back to overview]	Hypoglycaemic Episodes, Nocturnal
NCT00978627 (9) [back to overview]	Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT00978627 (9) [back to overview]	Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)
NCT00978627 (9) [back to overview]	Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT00978627 (9) [back to overview]	Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment
NCT00978627 (9) [back to overview]	Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment
NCT00978627 (9) [back to overview]	Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment
NCT00978627 (9) [back to overview]	Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT00978627 (9) [back to overview]	Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT00978627 (9) [back to overview]	Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26
NCT00998335 (12) [back to overview]	Metabolic Control as Measured by the Postprandial Plasma Glucose During the Day-long Plasma Glucose Profile.
NCT00998335 (12) [back to overview]	Percent Change From Baseline in Vascular Inflammatory Markers
NCT00998335 (12) [back to overview]	Plasma Lipid Concentration.
NCT00998335 (12) [back to overview]	Advanced Lipid Testing
NCT00998335 (12) [back to overview]	Number of Hypoglycemic Events
NCT00998335 (12) [back to overview]	Change in Anthropometric Measure (Body Weight).
NCT00998335 (12) [back to overview]	Change in Insulin Secretion
NCT00998335 (12) [back to overview]	Hepatic Steatosis
NCT00998335 (12) [back to overview]	Change in Anthropometric Measure (Body Mass Index [BMI]).
NCT00998335 (12) [back to overview]	Intramyocellular (IMCL) by Magnetic Resonance Imaging and Spectroscopy (MRS).
NCT00998335 (12) [back to overview]	Metabolic Control as Measured by the A1c
NCT00998335 (12) [back to overview]	Metabolic Control as Measured by the Fasting Plasma Glucose Concentration
NCT01003184 (14) [back to overview]	Change in Total Cholesterol From Baseline to Endpoint (Week 26).
NCT01003184 (14) [back to overview]	Change in Triglycerides From Baseline to Endpoint (Week 26).
NCT01003184 (14) [back to overview]	Changes in Systolic Blood Pressure From Baseline to Week 26
NCT01003184 (14) [back to overview]	Percentage of Patients Achieving ≤6.5% at Endpoint
NCT01003184 (14) [back to overview]	Percentage of Patients Achieving ≤7.0% at Endpoint
NCT01003184 (14) [back to overview]	Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26)
NCT01003184 (14) [back to overview]	Percentage of Patients Achieving HbA1c ≤7.4% at Endpoint
NCT01003184 (14) [back to overview]	Percentage of Patients Who Have Achieved HbA1c ≤7.4% With Weight Loss (≥1.0 kg) at Endpoint (Week 26)
NCT01003184 (14) [back to overview]	Hypoglycemia Rate Per Year
NCT01003184 (14) [back to overview]	Change in Body Weight From Baseline to Week 26
NCT01003184 (14) [back to overview]	Change in Diastolic Blood Pressure From Baseline to Week 26.
NCT01003184 (14) [back to overview]	Change in Fasting Serum Glucose From Baseline to Endpoint (Week 26).
NCT01003184 (14) [back to overview]	Change in HbA1c From Baseline to Week 26
NCT01003184 (14) [back to overview]	Change in High-density Lipoprotein (HDL) Cholesterol From Baseline to Endpoint (Week 26).
NCT01068652 (17) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c) After 14 Weeks of Treatment
NCT01068652 (17) [back to overview]	Mean of 8-point Plasma Glucose (PG) Profile After 38 Weeks of Treatment
NCT01068652 (17) [back to overview]	Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment
NCT01068652 (17) [back to overview]	Mean of 8-point Plasma Glucose (PG) Profile After 14 Weeks of Treatment
NCT01068652 (17) [back to overview]	Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 50 Weeks of Treatment
NCT01068652 (17) [back to overview]	Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 38 Weeks of Treatment
NCT01068652 (17) [back to overview]	Mean of Prandial Plasma Glucose (PG) Increment After 38 Weeks of Treatment
NCT01068652 (17) [back to overview]	Mean of Prandial Plasma Glucose (PG) Increment After 26 Weeks of Treatment
NCT01068652 (17) [back to overview]	Mean of Prandial Plasma Glucose (PG) Increment After 14 Weeks of Treatment
NCT01068652 (17) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c) at Week 50
NCT01068652 (17) [back to overview]	Glycosylated Haemoglobin (HbA1c)
NCT01068652 (17) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c) After 38 Weeks of Treatment
NCT01068652 (17) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment
NCT01068652 (17) [back to overview]	Mean of 8-point Plasma Glucose (PG) Profile After 26 Weeks of Treatment
NCT01068652 (17) [back to overview]	Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 26 Weeks of Treatment
NCT01068652 (17) [back to overview]	Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 14 Weeks of Treatment
NCT01068652 (17) [back to overview]	Mean of Prandial Plasma Glucose (PG) Increment After 50 Weeks of Treatment
NCT01074268 (11) [back to overview]	Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment
NCT01074268 (11) [back to overview]	Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)
NCT01074268 (11) [back to overview]	Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT01074268 (11) [back to overview]	Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT01074268 (11) [back to overview]	Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26
NCT01074268 (11) [back to overview]	Main Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 26 Weeks of Treatment
NCT01074268 (11) [back to overview]	Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment
NCT01074268 (11) [back to overview]	Extension Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
NCT01074268 (11) [back to overview]	Extension Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
NCT01074268 (11) [back to overview]	Extension Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52
NCT01074268 (11) [back to overview]	Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment
NCT01165684 (15) [back to overview]	Mean Plasma Glucose Increment Over 3 Meals (Breakfast, Lunch and Dinner) at Week 21
NCT01165684 (15) [back to overview]	Fasting Plasma Glucose (FPG) at Week 10
NCT01165684 (15) [back to overview]	Body Mass Index (BMI) at Week 32
NCT01165684 (15) [back to overview]	Body Weight at Week 32
NCT01165684 (15) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 10
NCT01165684 (15) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 21
NCT01165684 (15) [back to overview]	Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 32
NCT01165684 (15) [back to overview]	Mean Plasma Glucose Increment Over 3 Meals (Breakfast, Lunch and Dinner) at Week 32
NCT01165684 (15) [back to overview]	Fasting Plasma Glucose (FPG) at Week 21
NCT01165684 (15) [back to overview]	Fasting Plasma Glucose (FPG) at Week 32
NCT01165684 (15) [back to overview]	Hypoglycaemic Episodes (Rate of All Treatment Emergent Hypoglycaemia Episodes)
NCT01165684 (15) [back to overview]	Mean Plasma Glucose Increment Over 3 Meals (Breakfast, Lunch and Dinner) at Week 10
NCT01165684 (15) [back to overview]	Proportion of Subjects Reaching Glycosylated Haemoglobin (HbA1c) Below 7.0% at Week 32
NCT01165684 (15) [back to overview]	Proportion of Subjects Reaching Glycosylated Haemoglobin (HbA1c) Below 7.0% at Week 21
NCT01165684 (15) [back to overview]	Proportion of Subjects Reaching Glycosylated Haemoglobin (HbA1c) Below 7.0% at Week 10
NCT01186003 (1) [back to overview]	Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl)
NCT01232491 (7) [back to overview]	Rate of Treatment Emergent Adverse Events (TEAEs)
NCT01232491 (7) [back to overview]	Rate of Nocturnal Treatment Emergent Hypoglycaemic Episodes
NCT01232491 (7) [back to overview]	Rate of All Treatment Emergent Hypoglycaemic Episodes
NCT01232491 (7) [back to overview]	Change From Baseline in Glycosylated Haemoglobin (HbA1c)
NCT01232491 (7) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG)
NCT01232491 (7) [back to overview]	Change From Baseline in Body Weight
NCT01232491 (7) [back to overview]	Change From Baseline in Body Mass Index (BMI)
NCT01232946 (3) [back to overview]	Myocardial Glucose Uptake
NCT01232946 (3) [back to overview]	Myocardial Fatty Acid Oxidation Rate
NCT01232946 (3) [back to overview]	Myocardial Fatty Acid Esterification Rate
NCT01486966 (10) [back to overview]	Change From Baseline in Fructosamine After Two Weeks of Treatment
NCT01486966 (10) [back to overview]	Incidence of Hypoglycaemic Episodes
NCT01486966 (10) [back to overview]	Percentage of Subjects Achieving Mean 2hPPG of 3 Meals < 8.0 mmol / L After Two Weeks of Treatment
NCT01486966 (10) [back to overview]	Percentage of Subjects Achieving FPG Target Without Nocturnal Hypoglycaemia After Two Weeks of Treatment
NCT01486966 (10) [back to overview]	Percentage of Subjects Achieving FPG < 6.0 mmol / L After Two Weeks of Treatment
NCT01486966 (10) [back to overview]	Percentage of Subjects Achieving Both FPG and 2hPPG Targets After Two Weeks of Treatment
NCT01486966 (10) [back to overview]	Change From Baseline in Mean Value of Pre-lunch, Pre-dinner and Bedtime PG After Two Weeks of Treatment
NCT01486966 (10) [back to overview]	Change From Baseline in Mean 8-point Plasma Glucose (PG) After Two Weeks of Treatment
NCT01486966 (10) [back to overview]	Change From Baseline in Mean 2-hour Post Prandial Plasma Glucose (2hPPG) of 3 Meals After Two Weeks of Treatment
NCT01486966 (10) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) After Two Weeks of Treatment
NCT01513473 (10) [back to overview]	Number of Self-measured Hyperglycaemia (Episodes of PG Above 11.1 mmol/L (200 mg/dL))
NCT01513473 (10) [back to overview]	Number of Treatment Emergent Adverse Events (TEAEs)
NCT01513473 (10) [back to overview]	Steady-state Plasma Concentrations of Insulin Degludec and Insulin Detemir on Three Different Visits (Three Different Weeks) During the First 26 Weeks of Treatment
NCT01513473 (10) [back to overview]	Change From Baseline in Fasting Blood Glucose (FPG) at 26 Weeks (Analysed by Central Laboratory)
NCT01513473 (10) [back to overview]	Change From Baseline in HbA1c (%) at 52 Weeks (Analysed by Central Laboratory)
NCT01513473 (10) [back to overview]	Change From Baseline in Fasting Blood Glucose (FPG) at 52 Weeks (Analysed by Central Laboratory)
NCT01513473 (10) [back to overview]	Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory)
NCT01513473 (10) [back to overview]	Insulin Antibodies (Insulin Degludec Specific, Insulin Detemir Specific, Insulin Aspart Specific and Antibodies Cross-reacting to Human Insulin)
NCT01513473 (10) [back to overview]	Number of Episodes With Self Monitored Blood Ketones Above 1.5 mmol (Capillary Blood Ketone Measurement to be Performed if Self-measured Plasma Glucose (SMPG) Exceeds 14.0 mmol/l (250 mg/dL))
NCT01513473 (10) [back to overview]	Number of Hypoglycaemic Episodes
NCT01595646 (5) [back to overview]	Verbal Memory Composite
NCT01595646 (5) [back to overview]	Cerebral Spinal Fluid (CSF) Biomarkers of AD
NCT01595646 (5) [back to overview]	Cerebral Spinal Fluid (CSF) Biomarkers of AD TTau-P181/Abeta42 Ratio
NCT01595646 (5) [back to overview]	Functional Ability
NCT01595646 (5) [back to overview]	The Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog/Alzheimer's Disease Cooperative Study (ADCS)] - MCI Revision
NCT01831765 (8) [back to overview]	Change From Baseline in HbA1c (Post Meal Arm)
NCT01831765 (8) [back to overview]	Change in HbA1c
NCT01831765 (8) [back to overview]	Change in PPG (Postprandial Glucose)
NCT01831765 (8) [back to overview]	Change From Baseline in Body Weight
NCT01831765 (8) [back to overview]	Frequency of Adverse Events
NCT01831765 (8) [back to overview]	Number of Treatment Emergent Confirmed Hypoglycaemic Episodes
NCT01831765 (8) [back to overview]	Change From Baseline in 2-hour PPG (Postprandial Glucose) Increment (Meal Test)
NCT01831765 (8) [back to overview]	Change From Baseline in HbA1c (Glycosylated Haemoglobin)
NCT01835431 (7) [back to overview]	Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Plasma Glucose (PG) Below 3.1mmol/L (56mg/dL) or Severe Hypoglycaemia)
NCT01835431 (7) [back to overview]	Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L)
NCT01835431 (7) [back to overview]	Number of Treatment Emergent Nocturnal Confirmed Hypoglycaemic Episodes
NCT01835431 (7) [back to overview]	Change From Baseline in Fasting Plasma Glucose
NCT01835431 (7) [back to overview]	Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)
NCT01835431 (7) [back to overview]	Incidence of Treatment Emergent Adverse Events (TEAEs)
NCT01835431 (7) [back to overview]	Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill
NCT01868542 (7) [back to overview]	Proportion of Subjects Achieving HbA1c Below 7.0%
NCT01868542 (7) [back to overview]	Incidence of Hypoglycaemic Episodes : Nocturnal (23:00-05:59) and Over 24 Hours.
NCT01868542 (7) [back to overview]	Change in Fasting Plasma Glucose From Baseline
NCT01868542 (7) [back to overview]	Change in Fasting Plasma Glucose From Baseline
NCT01868542 (7) [back to overview]	Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline.
NCT01868542 (7) [back to overview]	Change in HbA1c
NCT01868542 (7) [back to overview]	Incidence of Adverse Events
NCT01966978 (8) [back to overview]	Composite End-point
NCT01966978 (8) [back to overview]	"Percentage of Participants Reaching Pre-specified Treatment Failure Outcome"
NCT01966978 (8) [back to overview]	Change in Short Form-36 (SF-36) Questionnaire Score
NCT01966978 (8) [back to overview]	Change in Diabetes Quality of Life (DQOL)Questionnaire Score- Least Squares Means
NCT01966978 (8) [back to overview]	Mean Change From Randomization in A1c at Week 26
NCT01966978 (8) [back to overview]	Hypoglycemic Episodes
NCT01966978 (8) [back to overview]	Mean Change From Randomization in Body Weight
NCT01966978 (8) [back to overview]	Percentage of Participants Reaching Target A1c of <7% at Week 26
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)
NCT02033889 (49) [back to overview]	Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104
NCT02033889 (49) [back to overview]	Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Time to Glycemic Rescue Therapy at Week 26
NCT02033889 (49) [back to overview]	Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
NCT02033889 (49) [back to overview]	Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
NCT02131272 (7) [back to overview]	Proportion of Subjects Achieving HbA1c Below 7.0%, Who Have Not Experienced Any Treatment Emergent Severe Hypoglycaemic Episodes Within the Last 14 Weeks of Treatment.
NCT02131272 (7) [back to overview]	Incidence of Adverse Events (AEs)
NCT02131272 (7) [back to overview]	Change in HbA1c (Glycosylated Haemoglobin)
NCT02131272 (7) [back to overview]	Change in Body Weight Standard Deviation Score (SDS)
NCT02131272 (7) [back to overview]	Proportion of Subjects Achieving HbA1c Below 7.5%, Who Have Not Experienced Any Treatment Emergent Severe Hypoglycaemic Episodes Within the Last 14 Weeks of Treatment
NCT02131272 (7) [back to overview]	Total Number of Treatment Emergent Nocturnal (23:00-06:59) Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
NCT02131272 (7) [back to overview]	Total Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
NCT02451137 (13) [back to overview]	Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia
NCT02451137 (13) [back to overview]	Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <3.0 mmol/L (<54 mg/dL) and/or Severe Hypoglycemia During the 6-Month Randomized Period
NCT02451137 (13) [back to overview]	Treatment Persistence Measured by Medication Possession Ratio (MPR)
NCT02451137 (13) [back to overview]	Scores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs) at Baseline, Month 6, Month 12
NCT02451137 (13) [back to overview]	Scores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Change Version (DTSQc) at Month 12
NCT02451137 (13) [back to overview]	Percentage of Participants With Hospitalizations, Emergency Rooms and Specialty Visits From Baseline to Month 6 and Month 12
NCT02451137 (13) [back to overview]	Percentage of Participants With at Least One Treatment-Emergent Hypoglycemia Event (Any Time of the Day, Nocturnal) Per Type of Hypoglycaemia During the Month 6 and Month 12 on Treatment Period
NCT02451137 (13) [back to overview]	Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <=3.9 mmol/L (<= 70 mg/dL) and <3.0 mmol/L (< 54 mg/dL) and/or Severe Hypoglycemia During the 12-Month Randomized Period
NCT02451137 (13) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6 and Month 12
NCT02451137 (13) [back to overview]	Change From Baseline in Body Weight at Month 6 and Month 12
NCT02451137 (13) [back to overview]	Change From Baseline in Basal Insulin Dose at Month 6 and Month 12
NCT02451137 (13) [back to overview]	"Percentage of Responders (Participants and Provider) Who Reported Excellent or Good Responses to Global Effectiveness Scale (GES) Question at Month 6, and Month 12"
NCT02451137 (13) [back to overview]	Change From Baseline in HbA1c at Month 6 and Month 12
NCT02741687 (10) [back to overview]	Length of Hospital Stay
NCT02741687 (10) [back to overview]	Number of Patients Transferred to the ICU Immediately After Surgery or During Hospitalization
NCT02741687 (10) [back to overview]	Number of Participants With Hypoglycemic Events
NCT02741687 (10) [back to overview]	Number of Days in the ICU
NCT02741687 (10) [back to overview]	Number of Participants Experiencing Stress Hyperglycemia
NCT02741687 (10) [back to overview]	Number of Participants With Emergency Room Visits After Discharge
NCT02741687 (10) [back to overview]	Number of Participants With Hospital Readmissions After Discharge
NCT02741687 (10) [back to overview]	Number of Patients Requiring Supplemental, Subcutaneous Insulin
NCT02741687 (10) [back to overview]	Total Daily Dose of Insulin for Patients Requiring Supplemental Insulin
NCT02741687 (10) [back to overview]	Number of Participants Experiencing Complications
NCT03377699 (24) [back to overview]	Number of Participants Who Developed Sight-threatening Retinopathy (Defined as Proliferative Retinopathy or Maculopathy) From Pregnancy Baseline to the End of Treatment (Yes/no)
NCT03377699 (24) [back to overview]	Number of Adverse Events in the Infant
NCT03377699 (24) [back to overview]	Number of Adverse Events During Pregnancy Period
NCT03377699 (24) [back to overview]	Last Planned Average Post-prandial Glucose Prior to Delivery (Average of Three Main Meals)
NCT03377699 (24) [back to overview]	Change in Body Weight From Pregnancy Baseline to Last Planned Visit Prior to Delivery
NCT03377699 (24) [back to overview]	Birth Weight Standard Deviation (SD) Score for Live Birth Infants
NCT03377699 (24) [back to overview]	Birth Weight for Live Birth Infants
NCT03377699 (24) [back to overview]	Number of Participants With Different Modes of Delivery e.g. Vaginal, Operative Vaginal, Planned Caesarean Section or Unplanned Caesarean Section Delivery
NCT03377699 (24) [back to overview]	Number of Participants With Early Foetal Death (Delivery Before 20 Completed GWs) (Yes/no)
NCT03377699 (24) [back to overview]	Number of Participants With HbA1c Below or Equal to 6.0% [42 Millimoles Per Mole (mmol/Mol)] From Last Planned HbA1c Prior to Delivery (Yes/no)
NCT03377699 (24) [back to overview]	Last Planned Fasting Plasma Glucose Prior to Delivery
NCT03377699 (24) [back to overview]	Number of Participants With HbA1c Below or Equal to 6.5% (48 mmol/Mol) From Last Planned HbA1c Prior to Delivery (Yes/no)
NCT03377699 (24) [back to overview]	Number of Participants With Live Born Infants (Yes/no)
NCT03377699 (24) [back to overview]	Number of Participants With Pre-eclampsia Defined as New-onset Hypertension Occurring From Gestational Week 20 to Delivery and Simultaneous Proteinuria or Presence of Eclampsia, HELLP Syndrome, or Other Severe Organ Involvement (Yes/no)
NCT03377699 (24) [back to overview]	Number of Participants With Pre-term Delivery
NCT03377699 (24) [back to overview]	Number of Participants With Presence of Major Abnormalities (Classified According to European Concerted Action on Congenital Anomalies and Twins (EUROCAT)) in Their Foetus/Infants
NCT03377699 (24) [back to overview]	Neonatal Hypoglycaemic Episodes Defined as Plasma Glucose Below or Equal to 1.7 mmol/L (31 mg/dL) or Below or Equal to 2.5 mmol/L (45 mg/dl) (Yes/no)
NCT03377699 (24) [back to overview]	Number of Participants Who Developed Sight-threatening Retinopathy Defined as Proliferative Retinopathy or Maculopathy From Treatment Baseline to the End of Treatment (Yes/no)
NCT03377699 (24) [back to overview]	Number of Live Born Infants With Birth Weight < 10th Percentile for Gestational Age and Sex (Local References) (Yes/no)
NCT03377699 (24) [back to overview]	Last Planned Glycosylated Haemoglobin (HbA1c) Prior to Delivery
NCT03377699 (24) [back to overview]	Number of Hypoglycaemic Episodes During the Pregnancy Period
NCT03377699 (24) [back to overview]	Number of Live Born Infants With Birth Weight > 90th Percentile for Gestational Age and Sex (Local References) [Yes/no]
NCT03377699 (24) [back to overview]	Number of Participants Who Had Neonatal Mortality (Death of Infant) (Yes/no)
NCT03377699 (24) [back to overview]	Number of Participants Who Had Perinatal Mortality (Death of Foetus/Infant ) (Yes/no)

Stroke in the Blood Pressure Trial.

Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years

Intervention	participants (Number)
BP Trial: Intensive Control	36
BP Trial: Standard Control	62

Intervention	participants (Number)
Glycemia Trial: Intensive Control	503
Glycemia Trial: Standard Control	543

Intervention	mg/dL (Mean)
	All timepoints excluding 3am	Fasting	Postprandial	3am
Biphasic Insulin Aspart 30 (Biphasic Insulin)	-59	-45	-68	-52
Insulin Aspart (Prandial Insulin)	-65	-23	-83	-34
Insulin Detemir (Basal Insulin)	-43	-59	-47	-40

Intervention	percentage of participants (Number)
	Total participants who achieved target	Subset who achieved target, n=18, 50, 39
Biphasic Insulin Aspart 30 (Biphasic Insulin)	17.0	52.5
Insulin Aspart (Prandial Insulin)	23.9	43.9
Insulin Detemir (Basal Insulin)	8.1	78.9

Intervention	hypoglycaemic events/participant/year (Median)
	All participants, Grade 1	All participants, Grade 2	All participants, Grade 3	All participants, Grade 2 or 3	Achieved HbA1c target, Grade 1, n=73, 70, 55	Achieved HbA1c target, Grade 2, n=73, 70, 55	Achieved HbA1c target, Grade 3, n=73, 70, 55	Achieved HbA1c target, Grade 2 or 3, n=73, 70, 55
Biphasic Insulin Aspart 30 (Biphasic Insulin)	3.8	3.0	0	3.0	3.0	2.7	0	3.0
Insulin Aspart (Prandial Insulin)	5.7	5.5	0	5.7	5.7	5.3	0	5.5
Insulin Detemir (Basal Insulin)	2.7	1.7	0	1.7	3.0	2.0	0	2.0

Intervention	percentage (%) of total haemoglobin (Mean)
	Baseline	Month 12
Biphasic Insulin Aspart 30 (Biphasic Insulin)	8.63	7.33
Insulin Aspart (Prandial Insulin)	8.55	7.20
Insulin Detemir (Basal Insulin)	8.45	7.64

Intervention	percentage (%) of total haemoglobin (Mean)
	Baseline	Month 36
Biphasic Insulin Aspart 30 (Biphasic Insulin)	8.63	7.22
Insulin Aspart (Prandial Insulin)	8.55	7.04
Insulin Detemir (Basal Insulin)	8.45	7.11

Intervention	units on a scale (Mean)
Insulin Detemir (Basal Insulin)	0.80
Insulin Aspart (Prandial Insulin)	0.77
Biphasic Insulin Aspart 30 (Biphasic Insulin)	0.76

Intervention	units on a scale (Mean)
Insulin Detemir (Basal Insulin)	0.78
Insulin Aspart (Prandial Insulin)	0.76
Biphasic Insulin Aspart 30 (Biphasic Insulin)	0.76

Intervention	percentage of participants (Number)
Insulin Detemir (Basal Insulin)	17.9
Insulin Aspart (Prandial Insulin)	4.2
Biphasic Insulin Aspart 30 (Biphasic Insulin)	8.9

Intervention	percentage of participants (Number)
Insulin Detemir (Basal Insulin)	43.2
Insulin Aspart (Prandial Insulin)	44.8
Biphasic Insulin Aspart 30 (Biphasic Insulin)	31.9

Intervention	Percent bound of total (Mean)
	Insulin detemir specific, week 0 (n=127, 112)	Insulin detemir specific, week 52 (n=125, 128)	Cross-reacting insulin, week 0 (n=130, 113)	Cross-reacting insulin, week 52 (n=132, 135)	Insulin aspart specific, week 0 (n=126, 111)	Insulin aspart specific, week 52 (n=128, 133)
Insulin Detemir	3.23	5.15	27.06	43.70	2.26	4.20
NPH Insulin	2.95	3.01	27.26	30.19	2.24	2.68

Intervention	Percent (%) of white blood cells (Mean)
	Baseline	Week 52	Change from Baseline to week 52
NN304	6.22	6.24	0.03
NN729	6.3	5.96	-0.32

Intervention	mmol/L (Mean)
	Baseline 1. point	Baseline 2. point	Baseline 3. point	Baseline 4. point	Baseline 5. point	Baseline 6. point	Baseline 7. point	Baseline 8. point	Baseline 9. point	Week 26 change. 1. point	Week 26 change. 2. point	Week 26 change. 3. point	Week 26 change. 4. point	Week 26 change. 5. point	Week 26 change. 6. point	Week 26 change. 7. point	Week 26 change. 8. point	Week 26 change. 9. point	Week 52 change. 1. point	Week 52 change. 2. point	Week 52 change. 3. point	Week 52 change. 4. point	Week 52 change. 5. point	Week 52 change. 6. point	Week 52 change. 7. point	Week 52 change. 8. point	Week 52 change. 9. point
NN304	8.17	8.95	7.66	8.60	8.29	8.43	8.69	7.97	8.05	-0.64	-0.61	-0.49	-0.34	-0.36	-0.35	-0.35	0.18	-0.64	-0.60	-0.54	-0.36	-0.78	-0.41	-0.31	-0.34	-0.24	-0.44
NN729	8.17	9.03	7.34	8.18	8.16	8.60	8.60	7.72	7.56	-0.44	-0.61	0.08	-0.22	-0.00	0.07	0.20	0.08	0.24	-0.67	-0.99	-0.28	-0.29	-0.59	-0.51	-0.47	-0.31	-0.09

Intervention	episodes (Number)
	All events - Major	All events - Minor	All events - Symptoms Only	Daytime - Major	Daytime - Minor	Daytime - Symptoms Only	Nocturnal - Major	Nocturnal - Minor	Nocturnal - Symptoms Only	Unclassified - Minor
NN304	21	3215	445	9	2741	381	12	472	64	2
NN729	21	2996	318	15	2590	258	6	404	60	2

Intervention	events (Number)
	Serious Adverse Events	Non-Serious Adverse Events
NN304	25	259
NN729	10	346

Intervention	percentage of participants (Number)
	Achieving HbA1c < 7% after 12 weeks, N=82	Not achieving HbA1c < 7% after 12 weeks, N=82	Achieving HbA1c < 7% after 20 weeks, N=81	Not achieving HbA1c < 7% after 20 weeks, N=81
Insulin Detemir	14.6	85.4	12.3	87.7

Intervention	episodes (Number)
	Occurence of hypoglycaemic episodes: Diurnal	Occurence of hypoglycaemic episodes: Nocturnal	Occurence of hypoglycaemic episodes: Total
Insulin Detemir	92	78	170

Intervention	percentage change in HbA1c (Mean)
	HbA1c at baseline	HbA1c at week 20	Change in HbA1c from baseline to week 20
Insulin Detemir	9.3	8.2	-1.2

Intervention	percentage change in HbA1c (Mean)
	HbA1c at baseline	HbA1c at week 12	Change in HbA1c from baseline to week 12
Insulin Detemir	9.3	8.2	-1.2

Intervention	mg/dL (Mean)
	FPG at baseline, N=81	FPG at week 12, N=77	FPG at week 20, N=78	Change in FPG from baseline to week 12, N=75	Change in FPG from baseline to week 20, N=73
Insulin Detemir	178	118	116	-60	-62

Intervention	kg (Least Squares Mean)
Group A (Phase 1 SYMLIN)	0.02
Group B (Phase 1 RA Insulin)	4.65

insulin detemir

Description

Cross-References

Synonyms (20)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (557)

Market Indicators

Research Demand Index: 74.85

Study Types

Clinical Trials (179)

Trial Overview

Trial Outcomes

Stroke in the Blood Pressure Trial.

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

Death From Any Cause in the Glycemia Trial.

Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 12 Months

Percentage of Participants (Total Participants and the Subset of Participants Who Did Not Have an Hypoglycaemic Episode) Achieving a Month 12 Value in HbA1c Below or Equal to 6.5%

Number of Hypoglycaemic Events Per Participant Per Year at Month 36 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%

HbA1c (Glycosylated Haemoglobin) at Month 12

Number of Hypoglycaemic Events Per Participant Per Year at Month 12 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%

HbA1c (Glycosylated Haemoglobin) at Month 36

Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 36 Months

Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 36 Months

Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 12 Months

Percentage of Participants Who Required A Second Insulin Therapy by Month 36

Percentage of Participants Who Required A Second Insulin Therapy by Month 12

Percentage of Participants Achieving a Month 36 Value in HbA1c Below or Equal to 6.5%

Number of Participants Having an 'Other' Adverse Event

Change From Baseline in Body Weight at Month 36

Change From Baseline in Body Weight at Month 12

Observed Insulin Antibody Values

Number of Subjects Reporting Adverse Events

Glycosylated Haemoglobin A1c (HbA1c)

Clinical Laboratory Values (Change in Haematology - Leucocytes)

Clinical Laboratory Values (Change in Haematology - Lymphocytes)

Clinical Laboratory Values (Change in Haematology - Monocytes)

Clinical Laboratory Values (Change in Haematology - Thrombocytes)

Glycaemic Control Parameters (9-point Self Measured Plasma Glucose [SMPG])

Glycaemic Control Parameters (Change in Fasting Plasma Glucose [FPG])

Glycaemic Control Parameters (Change in HbA1c)

Hypoglycaemic Episodes

Clinical Laboratory Values (Change in Haematology - Neutrophils)

Clinical Laboratory Values (Change in Biochemistry - Sodium)

Adverse Events

Clinical Laboratory Values (Change in Biochemistry - Alanine Aminotransferase [ALAT])

Clinical Laboratory Values (Change in Biochemistry - Albumin)

Clinical Laboratory Values (Change in Biochemistry - Alkaline Phosphatase [ALP])

Clinical Laboratory Values (Change in Biochemistry - Creatinine)

Clinical Laboratory Values (Change in Biochemistry - Lactate Dehydrogenase [LDH])

Clinical Laboratory Values (Change in Biochemistry - Potassium)

Clinical Laboratory Values (Change in Biochemistry - Total Protein)

Clinical Laboratory Values (Change in Haematology - Basophilis)

Clinical Laboratory Values (Change in Haematology - Eosinophils)

Clinical Laboratory Values (Change in Haematology - Haemoglobin)

Change From Baseline in Total Antibodies

Change From Baseline in Detemir Specific Antibodies

Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies

Percentage of Subjects Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than 7.0%

Occurence of Hypoglycaemic Episodes

Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 20

Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 12

Change in Fasting Plasma Glucose (FPG)

Change in Body Weight From Baseline at Week 24

Phase 2: Change in HbA1c at Week 36

Phase 2: Change in Body Weight at Week 36

Hypoglycemia Adverse Events

Fasting Serum Lipids Change From Baseline to Week 24

Intervention	Percent (Mean)
	Phase 1 Baseline	Change From Phase 1 Baseline to Week 36	Phase 2 Baseline at Week 24	Change From Phase 2 Baseline to Week 36
Group C (Phase 2 SYMLIN)	8.35	-1.96	6.26	0.14
Group D (Phase 2 SYMLIN+RA)	8.03	-0.68	7.57	-0.23
Group E (Phase 2 RA Insulin)	7.85	-1.49	6.14	0.22
Group F (Phase 2 RA Insulin + SYMLIN)	8.38	-0.99	7.32	0.07

Intervention	participants (Number)
	Mild	Moderate	Severe
Group A (Phase 1 SYMLIN)	31	12	0
Group B (Phase 1 RA Insulin)	46	13	0
Group C (Phase 2 SYMLIN)	7	0	0
Group D (Phase 2 SYMLIN+RA)	18	1	0
Group E (Phase 2 RA Insulin)	9	2	0
Group F (Phase 2 RA Insulin + SYMLIN)	19	3	0

Intervention	mg/dL (Mean)
	Total Cholesterol	HDL	LDL	Triglycerides
Group A (Phase 1 SYMLIN)	-1.81	1.11	2.36	-28.96
Group B (Phase 1 RA Insulin)	5.27	1.65	9.12	-31.98

Intervention	Percent (Number)
Group A (Phase 1 SYMLIN)	30.4
Group B (Phase 1 RA Insulin)	10.7

Intervention	Percent (Number)
Group A (Phase 1 SYMLIN)	44.6
Group B (Phase 1 RA Insulin)	55.4

Intervention	cm (Least Squares Mean)
Group A (Phase 1 SYMLIN)	-0.63
Group B (Phase 1 RA Insulin)	2.17

Intervention	Percent (Least Squares Mean)
Group A (Phase 1 SYMLIN)	-1.11
Group B (Phase 1 RA Insulin)	-1.27

Intervention	mg/dL (Mean)
Group A (Phase 1 SYMLIN)	-29.0
Group B (Phase 1 RA Insulin)	-37.8

Intervention	Percent (Number)
Group A (Phase 1 SYMLIN)	46.4
Group B (Phase 1 RA Insulin)	14.3

Intervention	mmol/L (Mean)
	Visit P1 IDet (N)=138, NPH (N)=146	FU Visit IDet (N)=138, NPH (N)=146	Change from Visit P1-FU (N=136, 145)
Insulin Detemir	7.64	7.81	0.16
Neutral Protamine Hagedorn (NPH) Insulin	7.64	7.69	0.05